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Numerous studies have demonstrated the impact of organic cation (OCTs; SLC22 family) 
and anion transporters (OATs; SLC22 family) on the efficacy and safety of clinically important 
therapeutics. To be specific, OCTs and OATs have been identified as determinants for uptake into 
and secretion from enterocytes, hepatocytes and renal proximal tubular cells, and are frequent sites 
of drug-drug interaction (DDI). In addition, OCTs expressed in brain are components of the low-
affinity, high capacity clearance pathway (uptake-2) for biogenic monoamine neurotransmitters. 
As a result, OCTs may represent novel targets for mood disorders.  
xv 
 
 
 
The inhibitory effects of several therapeutic agents, designed drugs and novel compounds 
were assessed on the function of OCTs/Octs and OATs/Oats. Among these compounds, the 
anthraquinone rhein showed significant inhibition on hOATs. While the antituberculosis drug 
ethambutol, the herbal products matrine and oxymatrine, synthetic cathinones, and all quinazoline 
and guanidine compounds produced significant inhibition on hOCT activity with most IC50 values 
in the micro- and even nanomolar ranges.  
Considering the clinically relevant unbound concentrations in biofluids, significant DDI 
potentials were found for rhein, ethambutol, matrine, oxymatrine and several synthetic cathinones 
affecting enterocytes, hepatocytes and/or proximal tubules. As hOCT2 and hOCT3 may participate 
in modulating neurotransmitter homeostasis in the CNS, these findings also suggested that the 
CNS pharmacological effects of synthetic cathinones, quinazoline and guanidine compounds 
might be due to their inhibitory effects on OCTs; although their impact may be limited solely to 
clearance of these compounds. Based upon their in vitro OCT/Oct inhibition profiles, three lead 
quinazoline and guanidine compounds were chosen for in vivo studies. Potent antidepressant-like 
effects of one lead hOCT-interacting compound (KEO-099) were re-confirmed in the tail 
suspension test. While in vivo results of the two newly identified hOCT-interacting lead 
compounds were somewhat less clear. 
Finally, homology modeling and docking studies for hOCT3 identified key amino acid 
residues that might be involved in interaction between hOCT3 and small molecules. Subsequent 
experiments confirmed a competitive mode of interaction between MPP+ and lead compounds on 
hOCT3. Thus, preliminary analysis indicates our hOCT3 homology model can be used to support 
rational drug design and high-throughput screening of novel hOCT substrates/inhibitors.   
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CHAPTER 1 
 
 
THE SLC22 TRANSPORTER FAMILY: NOVEL INSIGHTS TO ROLES IN DRUG 
EFFICACY, DRUG-DRUG INTERACTIONS AND MOOD DISORDERS 
 
  
 
 
1.A  OVERVIEW OF ORGANIC CATION AND ANION TRANSPORTERS 
Remarkable progress has been achieved in understanding the vital role of transporters in 
mediating transcellular movement of endogenous and exogenous substances in the body [1]. 
Among these transporters, organic cation (OCTs) and anion transporters (OATs), belonging to the 
solute carrier 22 (SLC22) family, interact with hundreds of cationic, anionic and zwitterionic 
organic molecules [1-3]. OCTs and OATs are characterized by 12 α-helical transmembrane 
domains (TMDs), a large extracellular loop located between TMDs 1 and 2, a large intracellular 
loop between TMDs 6 and 7, and intracellular N- and C-termini [4]. OCTs and OATs utilize 
different mechanisms to transport organic charged molecules across the cell membranes (Figure 
1.1). Uptake of organic cations into the negatively charged intracellular environment is 
electrochemically a downhill process, and OCTs utilize this gradient as their driving forces 
functioning as facilitated diffusion carriers [5]. For uptake, OATs function as tertiary active 
transporters that are indirectly coupled to Na+/K+-ATPase and Na+/dicarboxylate cotransporter 
function (Figure 1.1). They utilize the stored energy of α- ketoglutarate (α-KG) gradient to drive 
organic anion exchange [2, 6]. The first SLC22 family member, Oct1, was cloned from rat kidney 
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in 1994, and Oat1 was cloned from rat kidney in 1997 [7-9]. Three major OCT subtypes (i.e., 
OCT1, OCT2, and OCT3), and five major OAT subtypes (OAT1-4 and URAT1), as well as 
OCT/OAT orthologs, have been identified [2, 3]. Extensive investigations have focused on the 
structure, regional distribution and function of OCTs and OATs [2, 3]. The expression of OCTs 
and OATs have been confirmed in a number mammalian species such as human, mouse, rat and 
rabbit [2-4]. OAT1-3 and OCT1-3 mediate cellular entry or reuptake of small organic anions and 
cations, respectively [2, 3, 6]. The role of OAT4 in renal secretion and absorption is less well 
defined [2, 6].         
While isolated from kidney, it has now been confirmed that OCT1/Oct1 exhibit a broad 
tissue distribution in peripheral organs. In humans, OCT1 showed strongest mRNA expression in 
liver compared to any other tissues [10]. A recent study using a quantitative proteomics approach 
showed that the protein expression of OCT1 in human liver appears to be greater than any other 
hepatobiliary transporters, including BCRP, BSEP, MATE1, MDR1, MRP2, MRP3, NTCP, 
OATP1B1, OAPT1B3 and OATP2B1 [11]. In rodents, marked mRNA and protein expression of 
Oct1 was found in liver, kidney and intestine [10]. OCT1/Oct1 was located in the membrane of 
these tissues, e.g. sinusoidal membrane of hepatocytes and basolateral membrane of enterocytes 
[3]. OCT1/Oct1 has a broad substrate specificity. Hundreds of clinical therapeutics, such as 
metformin, lamuvidine, acyclovir, ganciclovir, pentamidine and furamidine, have been identified 
as substrates and/or inhibitors [4]. 
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Figure 1.1 Renal cell model depicting the various driving forces for organic cation and anion 
transport and the SLC22 transporters studied in this work.   
 
Upper panel: schematic model of the transport processes associated with uptake and efflux of 
organic cations and anions. Lower panel: SLC22 transporters expressed in the proximal tubular 
cells in kidney. α-KG, α-ketoglutarate; OA-, organic anion; OC+: organic cation; OAT: organic 
anion transporter; OCT: organic cation transporter.  
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Oct2 was cloned from rat kidney in 1996 [12]. Later, OCT2/Oct2 was identified in human, 
rat, mouse, rabbit and pig [13]. Unlike OCT1/Oct1, OCT2/Oct2 is mainly located in kidney, with 
marked expression at the basolateral membrane of proximal tubular cells. OCT2/Oct2 plays an 
important role in renal active secretion of cationic substances [3]. Although the expression of 
OCT2/Oct2 has been found in a variety of organs including kidney, small intestine, lung, skin, 
brain and choroid plexus, mRNA and immunohistochemical evidence suggested that OCT2/Oct2 
is not expressed in human or rodent liver [3]. Evidence for overlapping substrate specificity was 
observed between OCT1 and OCT2. Typical substrates and inhibitors for OCT2 include 
endogenous substances (e.g. choline, dopamine (DA), norepinephrine (NE), epinephrine, 
serotonin (5-HT), and histamine H2 receptor antagonists (e.g. cimetidine, famotidine, and 
ranitidine), and anti-cancer (e.g. cisplatin) and antihypertensive (e.g. debrisoquine) agents [13]. 
In 1998, OCT3/Oct3 was cloned from both human central nervous system (CNS) and rat 
placenta [14, 15]. Two years later, mouse Oct3 was cloned from kidney [16]. Compared with 
OCT1/Oct1 and OCT2/Oct2, OCT3/Oct3 exhibits a wider tissue expression. In addition to liver 
and kidney, OCT3/Oct3 was identified in heart, skeletal muscle, brain, small intestine, liver, lung, 
kidneys, urinary bladder, mammary gland, cornea skin, blood vessels and tumor cells [4]. OCT3 
protein was localized to the basolateral membrane of the trophoblast in placenta [17], the 
sinusoidal membrane of hepatocytes [18], the apical membrane of enterocytes [19] and the luminal 
membrane of lung epithelial cells [20]. It is involved in the uptake of organic cationic molecules 
into these tissues. OCT3/Oct3 showed great similarity with OCT1/Oct1 and OCT2/Oct2 in terms 
of substrate specificity, and a broad range of endogenous and exogenous organic cations have been 
proved as its substrate and/or inhibitors [4]. 
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rOat1 was cloned from rat kidney using the Xenopus oocyte expression system in 1997 [7, 
9]. Several other Oat1 orthologs were later identified in mouse, C. elegans, flounder, rabbit pig 
and human [21-28]. Oat1 mRNA was expressed abundantly in kidney, olfactory mucosa and 
choroid plexus [29-31]. In addition, rOat1 was targeted to the basolateral membrane of renal 
tubules using an Oat1/green-fluorescent protein fusion construct [32]. Immunohistochemical 
studies confirmed the basolateral expression of hOAT1, rOat1 and mOat1 in the proximal tubule 
cells [7, 9, 25]. Interestingly, male mice expressed a higher level of mRNA for mOat1 than female 
mice [33]. hOAT1/mOat1 mediates transport of a broad variety of drugs and endogenous 
compounds including nonsteroidal anti-inflammatory drugs (ibuprofen, indomethacin and 
ketoprofen), antivirals (e.g., adefovir and cidofovir), histamine H2-blockers (e.g., cimetidine), and 
endogenous compounds (e.g., prostaglandin E2, α-KG and urate) [6].     
rOat2 and hOAT2 mRNA are expressed in both liver and kidney, while mOat2 mRNA is 
predominantly expressed in kidney with a weaker expression in liver [34, 35]. The protein of 
hOAT2 was immunolocalized to the basolateral membrane of renal proximal tubules [36]. 
hOAT2/mOat2 function is the least studied of all the OATs, but identified substrates include 
glutarate, methotrexate, bumetanide and indomethacin [6].  
rOat3 was isolated from rat brain in 1999 [37], and its orthologs were later identified in 
various tissues in mouse, rabbit, pig, and human [29, 38, 39]. The mRNA of mOat3 was abundantly 
expressed in kidney, eye tissues and brain [40], while rOat3 mRNA was detected in kidney, liver 
and brain [41]. On the contrary, a predominant expression of hOAT3 mRNA was noted in human 
kidney, brain and skeletal muscle, with no signal detected in liver [42]. Immunohistochemistry 
demonstrated that hOAT3 and rOat3 are expressed on the basolateral membrane of the renal 
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proximal tubule [38, 43]. OAT3/Oat3 shares a high similarity with OAT1/Oat1 and OAT2/Oat2 
in terms of substrate specificity [6].  
hOAT4 mRNA is only expressed in the kidney and placenta of higher primates [44-46]. It 
was demonstrated that hOAT4 was targeted to the apical membrane of renal proximal tubule using 
immunohistochemistry [44, 47]. In placenta, hOAT4 protein was localized to the basolateral 
membrane of the syncytiotrophoblast [42, 48]. Studies suggested that a broad variety of drugs 
interact with hOAT4 as substrates or inhibitors, including nonsteroidal anti-inflammatory drugs 
(ibuprofen and ketoprofen), furosemide, methotrexate, penicillin G and probenecid [6].  
1.B EXPRESSION OF ORGANIC CATION AND ANION TRANSPORTERS IN BRAIN  
The mammalian brain has its own security system, known as the blood-brain barrier (BBB) 
and the blood-cerebrospinal fluid (CSF) barrier to protect it from the circulating metabolites, drugs, 
toxins and blood-borne pathogens [49]. In brain, choroid plexuses (CPs) are localized in the 
ventricular system [50]. They occur in each of the four major cisternae, which are developed from 
the median wall of the lateral ventricles and the roof of the third and fourth ventricles [50]. As a 
tight epithelial barrier, they form the interface between the blood and the CSF [51]. In the CNS, 
CPs are the main site of secretion of the CSF [52]. They are also involved in transporting 
compounds into or out of brain. Previous studies have demonstrated that OCTs and OATs are 
expressed in the CPs [52]. The mRNA of Oat1, Oat2 and Oat3 were detected in the CPs of mice 
and rats [29, 31, 41, 53]. In addition, the protein expression of rOat1 and rOat3 were identified on 
the apical CP membranes using green fluorescent fusion proteins, Western blot analysis, and 
immunohistochemical staining [31, 54]. Furthermore, significantly impaired accumulation of OAT 
substrates such as fluorescein-methotrexate was observed in isolated choroid plexus tissues from 
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Oat3 knockout mice as compared with wild-type mice [29, 55]. The active transport of cationic 
compounds, including choline and quinacrine in rat choroid plexus cells were also observed, 
indicating a specific mechanism for organic cation transcellular movement as well (Table 1.1) [56, 
57]. A further study confirmed that mRNA expression of Oct2 and Oct3, but not Oct1, was 
detected in rat CP, and Oct2 was located in the apical membrane of rat CP epithelial cells using an 
Oct2/green fluorescent protein fusion construct [1]. However, Choudhuri et al. reported that 
mRNA level of Oct1 and Oct3 was detectable in rat CP, while Oct2 expression was virtually 
nonexistent in CP [58]. In mouse, the mRNA expression of Oct2 has been identified in CP, while 
the expression of Oct1 and Oct3 were not detectable [59]. However, the mRNA of OCT1, OCT2, 
and OCT3 is expressed in human CP, and OCT1 was found as the most abundant transporter 
among the three transporters [59].   
In addition to blood-CSF barrier, BBB is a highly selective barrier that separates the 
circulating blood from the brain extracellular fluid in the CNS. Vessel endothelial cells are 
connected by tight junctions producing an extremely high electrical resistivity; therefore, 
transporters play a vital role in regulating exchange of endogenous and exogenous substances 
between blood and brain [60]. The expression of Oat3 and OCTs/Octs have been identified in 
human and rodent, while the results are controversial (Table 1.2) [52, 61, 62]. Several studies have 
reported the mRNA expression of mOat3 and rOat3 in brain capillaries, and the protein expression 
of mOat3 and rOat3 was localized to the basolateral membrane of brain capillary endothelial cells 
using western blotting and immunohistochemical analysis [63-66] Lin et al. studied the cellular 
localization of OCT1/Oct1 and OCT2/Oct2 in isolated brain microvessel endothelial cells 
(BMECs) from human, rat, and mouse [61].  Both mRNA and protein expressions of OCT1/Oct1 
and OCT2/Oct2 were observed in BMECs from these species, as well as in immortalized adult rat 
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brain endothelial cells [61, 67]. In addition, immunocytochemistry showed that these OCTs/Octs 
were mainly expressed on the luminal side of BMECs, which was confirmed by siRNA 
knockdown of OCT1/Oct1 and OCT2/Oct2 in primary BMECs [61]. In contrast, another study 
failed to measure Oct1 and Oct2 mRNA expression by quantitative PCR analysis in freshly 
isolated mouse brain capillaries, except for a negligible level of Oct3 mRNA [62]. Additionally, 
no capillary associated fluorescence was detected by immunocytochemistry in brain sections [62]. 
Several recent studies investigated the expression of OCT1, OCT2 and OCT3 in human blood 
brain barrier. Dickens confirmed that OCT1 and OCT3 mRNA expression was detectable in 
hCMEC/D3 cells, a model of the human blood brain barrier; while OCT2 mRNA expression was 
undetectable [68]. The protein expression of OCT1 in hCMEC/D3 cells was confirmed by 
immunoblotting [68]. Another study demonstrated that the mRNA for OCT3 was presented in 
human brain vascular smooth muscle cells, while the mRNA of OCT1 and OCT2 was absent [69]. 
Finally, a recent study showed that mRNAs of OCT1, OCT2 and OCT3 were detected in isolated 
human brain microvessels and the protein expression of OCT3 was verified by 
immunofluorescence staining [70]. Friedrich et al. reported that Oct1, but not Oct2 or Oct3, was 
expressed in the rat brain microvessel endothelial cell line RBE4 by northern blotting and RT-PCR 
[71]. However, another independent study showed a low mRNA level of Oct2 and Oct3, in rat 
brain capillary endothelial cell line TR-BBB13 [72]. In mouse brain microvessel cell line MBEC4, 
Oct2 but not Oct1 mRNA was identified [73]. Although these studies showed conflicting results, 
which appear to be dependent on experimental models (cell lines or tissues), these data support 
that OCTs/Octs play an active role in the CNS permeation of organic cations. Further work is 
necessary to validate these in vitro models, measure the expression of OCTs/Octs, and 
quantitatively evaluate their contribution in mediating brain uptake of organic cations in vivo. 
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Interestingly, a variety of studies demonstrated that OCT2/Oct2 and OCT3/Oct3 are also 
expressed in the neurons (Figure 1.2, Table 1.3). Busch et al. quantified OCT2 expression in human 
brain tissues, and they found that mRNA and protein expression of OCT2 were identified in 
neurons in the cerebral cortex and various subcortical nuclei [74]. Another study showed OCT3 
mRNA expression in various parts of human brain, including spinal cord, medulla oblongata, 
caudate nucleus, cerebral cortex, hippocampus, substantia nigra, medulla oblongata, cerebellum, 
nucleus accumbens and Pons [75]. A recent study also reported that mRNA expression of OCT2 
and OCT3 was quantifiable in a human astrocytoma-derived cell line, 1321N1 [76]. As rodents 
are widely used animal models for neurological study, extensive investigations have been 
conducted to exhibit the distribution of Oct2 and Oct3 in mouse and rat brain. 
In mouse brain, the mRNA and protein of Oct1 were found in brain stratum and cerebral 
cortex (Table 1.4) [67]. A high level of protein expression of Oct2 was found in the frontal cortex, 
hippocampus and amygdale [67, 77], which was consistent with a previous study shown that Oct2 
mRNA expression was observed in the cerebellum and hippocampus (Table 1.4) [78]. Oct2 protein 
expression was also detected in some aminergic neuron-containing areas including the locus 
coeruleus (most noradrenergic neurons) and dorsal raphe (some serotonergic neurons) [77]. 
However, Oct2 expression was not observed in substantia nigra or ventral tegmental area [77]. A 
recent study confirmed Oct2 expression in mouse brain (infralimbic cortices, hippocampus, 
amygdala, dorsomedial and arcuate nuclei of hypothalamus) [79]. In addition to Oct1 and Oct2, 
Oct3 was widely distributed in mouse brain. In 2004, Vialou et al. reported that OCT3 was 
distributed throughout the brain and highly expressed in circumventricular organs such as area 
postrema and subfornical organ [80]. Another study showed Oct3 mRNA expression in 
raphe nuclei, striatum and thalamus, implicating monoaminergic pathways [78]. Further studies 
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focused on expression of mOct3 in neurons and astrocytes [80, 81]. According to Vialou et al., 
Oct3 protein expression was identified in dopaminergic neurons of substantia nigra compacta, non-
aminergic neurons of the ventral tegmental area, substantia nigra reticulata, locus coeruleus, 
hippocampus and cortex, as well as the astrocytes in the substantia nigra reticulata, hippocampus 
and hypothalamic nuclei [80]. However, Cui et al. claimed that Oct3 was expressed in the 
nigrostriatal astrocytes, but not in the astrocytes from regions such as cerebellum, hippocampus, 
and cortex [81]. Additionally, no Oct3 expression was observed in dopaminergic structures from 
ventral midbrain and striatum [81].  
In 1998, Oct3 mRNA expression was identified from rat brain tissue, especially in 
cerebellum, hippocampus, pontine nuclei and cortex (Table 1.4) [82]. Ten years later, several 
groups confirmed that Oct3 protein expression was throughout the rat brain, with the highest level 
observed in the superior and inferior colliculi, islands of Calleja, subiculum, lateral septum, lateral 
and dorsomedial hypothalamic nuclei, granule cell layers of the main and accessory olfactory bulbs, 
the cerebellum, the retrosplenial granular cortex, circumventricular organs, and the linings of all 
cerebral ventricles [83, 84]. A further study from Gasser’s group showed that Oct3 was expressed 
in most neurons of the intercalated cell groups of the amygdala of rat brain, and it shows co-
distributed with the areas of dense D1 receptor expression [85]. Oct2 was found to be localized in 
cholinergic nerve terminals (C-terminals) and endplates that correspond to the presynaptic 
terminals of cholinergic motoneurons of the anterior horn [86]. In addition, Oct2 might also exist 
on synaptic vesicles at presynaptic terminals, based on the results from immunoelectron 
microscopy [86]. 
In summary, both Oct2 and Oct3 were expressed in the main aminergic projection regions 
in rodent brain, including the cortex, hippocampus, thalamus, hypothalamus, amygdala and 
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hindbrain [74, 77, 80, 83]. They also showed marked expression in aminergic nuclei, raphe, locus 
coeruleus and the tuberomammillary nucleus [74, 77, 80, 83]. However, OCT2/Oct2 and 
OCT3/Oct3 showed differences in distribution (subregions and nuclei) and relative expression 
levels. OCT3 showed relatively higher expression in circumventricular organs [80, 87] and Oct3 
might be the only OCT isoform expressed in dopaminergic nuclei substantia nigra [83]. In addition, 
the expression of Oct3 in the astrocytes in the dorsomedial hypothalamus nucleus and substantia 
nigra indicated that OCT3/Oct3, rather than Oct2, might be involved in mediating extracellular 5-
HT level [80, 81, 88]. 
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Table 1.1 Expression of OCTs/Octs in choroid plexus.   
 Species Level Expression Localization Techniques References 
OCT1/Oct1 
Mouse mRNA －  RT-PCR [59] 
Rat mRNA ?  RT-PCR [1, 58] 
Human mRNA +  RT-PCR [59] 
OCT2/Oct2 
Mouse mRNA +  RT-PCR [59, 67] 
Rat 
mRNA ?  RT-PCR [1, 58, 78] 
Protein + 
Apical Membrane of CP 
epithelial cells 
Green Fluorescent 
Protein Fusion 
[1] 
Human mRNA +  RT-PCR [59] 
OCT3/Oct3 
Mouse mRNA －  RT-PCR [59, 67] 
Rat 
mRNA and 
protein 
+  
RT-PCR and 
Immunohistochemistry 
[1, 58, 78, 89] 
Human mRNA +  RT-PCR [59] 
＋
: indicates transporter expression;  
－
: indicates no expression detected. 
? : controversial study results.   
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Table 1.2 Expression of OCTs/Octs in blood brain barrier.   
 Species Level Expression Localization Techniques References 
OCT1/Oct1 
Mouse 
mRNA ?  RT-PCR [62, 67, 73] 
Protein + 
Luminal and abluminal 
 side of  BMECsa 
Confocal microscopy, western blot 
and immunohistochemistry 
[61, 67] 
Rat 
mRNA +  Northern blotting and RT-PCR [71, 72] 
Protein + 
Luminal and abluminal 
 side of  BMECs 
Confocal microscopy 
 and western blot 
[61] 
Human 
mRNA +  RT-PCR [68, 70] 
Protein + 
Luminal and abluminal 
 side of  BMECs 
Confocal microscopy and western blot [61] 
 
OCT2/Oct2 
Mouse 
mRNA ?  RT-PCR [62, 73] 
Protein + 
Luminal and abluminal 
 side of  BMECs 
Confocal microscopy, western blot 
and immunofluorescence 
[61, 67] 
Rat 
mRNA ?  Northern blotting and RT-PCR [71, 72] 
Protein + 
Luminal and abluminal 
 side of  BMECs 
Confocal microscopy and western blot [61] 
Human 
mRNA ?  RT-PCR [68, 70] 
Protein + 
Luminal and abluminal side 
of  BMECs 
Confocal microscopy and western blot [61] 
OCT3/Oct3 
Mouse mRNA +  RT-PCR [62] 
Rat mRNA ?  Northern blotting and RT-PCR [71, 72] 
Human mRNA +  RT-PCR [68-70] 
  protein +  Immunofluorescence staining [70] 
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a: BMECs, brain microvascular endothelial cells;  
b: IHC, immunohistochemistry;  
＋
: indicates transporter expression;  
－
: indicates no expression detected; 
? : controversial study results.   
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Table 1.3 Expression of OCTs/Octs in neuron and glia cells.   
 Species Localization Expression Level Techniques References 
OCT1/Oct1 
Mouse  + mRNA and protein RT-PCR and Immunohistochemistry [67] 
Rat  + mRNA In situ hybridization [78] 
Human  － mRNA Northern blot [74] 
OCT2/Oct2 
Mouse 
Neurons + Protein Immunofluorescent histochemistry [77] 
Astrocytes － Protein Immunofluorescent histochemistry [77] 
Rat Neurons + Protein Immunohistochemistry [86] 
Human Neurons + mRNA and protein 
Northern blot, in situ hybridization 
and Western blot 
[74, 76] 
OCT3/Oct3 
Mouse 
Neurons ? Protein Immunohistochemistry [80, 81] 
Glial cells + Protein Immunohistochemistry [80, 81] 
Rat 
Neurons + mRNA and protein 
In situ hybridization and 
immunohistochemistry 
[82, 85, 89] 
Glial cells ? Protein Immunohistochemistry [88, 89] 
Pinealocyte + Protein Immunohistochemistry [89] 
Human 
Neurons + Protein Immunohistochemistry [81] 
Astrocytes + mRNA and protein RT-PCR and immunohistochemistry [76, 81] 
＋
: indicates transporter expression; 
－
: indicates no expression detected.  
? : controversial study results.   
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Table 1.4 Expression of OCTs/Octs in different brain regions.     
 Species Localization Expression Level Techniques References 
OCT1/Oct1 
Mouse 
Cerebral cortex + mRNA and protein 
RT-PCR and 
immunohistochemistry 
[67] 
Brain striatum + Protein Immunohistochemistry [67] 
Rat 
Cerebellum + mRNA In situ hybridization [78] 
Corpus callosum 
 (white matter) 
+ mRNA In situ hybridization [78] 
Human  － mRNA Northern blotting [74] 
OCT2/Oct2 
Mouse 
Amygdala + Protein Immunofluorescent histochemistry [77] 
Brain striatum + Protein Immunohistochemistry [67] 
Cerebral cortex + mRNA and protein 
RT-PCR and immunofluorescent 
histochemistry 
[67] 
Dorsal raphe + Protein Immunofluorescent histochemistry [77] 
Frontal cortex + Protein Immunofluorescent histochemistry [77] 
Hippocampus + Protein Immunofluorescent histochemistry [77] 
Locus coeruleus + Protein Immunofluorescent histochemistry [77] 
Rat 
Cerebellum + mRNA In situ hybridization [78] 
The third ventricle 
layer boarding 
+ mRNA In situ hybridization [78] 
Hippocampus + mRNA In situ hybridization [78] 
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 Species Localization Expression Level Techniques References 
Human 
Amygdaloideus 
nucleus  
+ mRNA Northern blot [74] 
Caudatus nucleus  + mRNA Northern blot [74] 
Cerebral cortex + mRNA In situ hybridization [74] 
Hippocampus + mRNA and protein 
Northern blot, in situ hybridization 
and western blot 
[74] 
Subthalamicus 
nucleus 
+ mRNA Northern blot [74] 
Substantia nigra + mRNA Northern blot  [74] 
Thalamus + mRNA Northern blot [74] 
OCT3/Oct3 Mouse 
Cerebral cortex + mRNA RT-PCR [67] 
Dentate gyrus + Protein Immunohistochemistry [80] 
Dorsal raphe + Protein Immunohistochemistry [80] 
Frontal cortex + Protein Immunohistochemistry [80] 
Hippocampus + Protein Immunohistochemistry [80] 
Striatum + Protein Immunohistochemistry [81] 
Subfornical organ + Protein Immunohistochemistry [89] 
Substantia nigra + Protein Immunohistochemistry [80, 81] 
Ventral tegmental 
area 
+ Protein Immunohistochemistry [80] 
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 Species Localization Expression Level Techniques References 
Rat 
Amygdala + Protein 
Western blot and 
immunohistochemistry 
[83, 85] 
Area postrema + Protein Immunohistochemistry [83, 89] 
Brainstem + Protein Western blotting [83] 
Cerebellum + mRNA and protein 
In situ hybridization and 
immunohistochemistry 
[82, 83, 88, 
89] 
Cerebral cortex + mRNA In situ hybridization [78, 82] 
Dorsal raphe + mRNA and protein 
In situ hybridization and 
immunohistochemistry 
[78, 83, 88, 
89] 
Frontal cortex + Protein Immunohistochemistry [83, 84, 89] 
Hypothalamic 
nuclei 
+ mRNA and protein 
In situ hybridization and 
immunohistochemistry 
[78, 83, 88, 
89] 
Hippocampus + mRNA and protein 
RT-PCR, in situ hybridization, 
Western blot and 
immunohistochemistry 
[78, 82-84, 
89] 
Lateral geniculate 
nucleus 
+ mRNA In situ hybridization [78] 
Lateral septum + mRNA In situ hybridization [78] 
Locus coeruleus + Protein Immunohistochemistry [83, 89] 
Medial preoptic 
nuclei 
+ Protein Immunohistochemistry [89] 
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 Species Localization Expression Level Techniques References 
Olfactory bulbs + Protein Immunohistochemistry [83] 
Pontine nucleus + mRNA In situ hybridization [82] 
Pineal gland + Protein Immunohistochemistry [89] 
Striatum + mRNA In situ hybridization [78, 83, 84] 
Septal complex + Protein Western blot [83] 
Subcommissural 
organ 
+ Protein Immunohistochemistry [83, 89] 
Subfornical organ + mRNA and protein 
In situ hybridization and 
immunohistochemistry 
[78, 83, 89] 
Substantia nigra + Protein Immunohistochemistry [83, 89] 
Supraoptic nuclei + Protein Immunohistochemistry [83, 89] 
Thalamus + mRNA In situ hybridization [78] 
White matter + Protein Western blot  [83] 
Human 
Caudate Nucleus + mRNA RT-PCR [75] 
Cerebellum + mRNA RT-PCR [75] 
Cerebral Cortex + mRNA RT-PCR [75] 
Medulla 
Oblongata 
+ mRNA RT-PCR [75] 
Nucleus 
accumbens 
+ mRNA RT-PCR [75] 
Hippocampus + mRNA RT-PCR [75] 
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 Species Localization Expression Level Techniques References 
Substantia nigra + mRNA RT-PCR [75] 
Pons + mRNA RT-PCR [75] 
  
＋
: indicates transporter expression; 
  
－
: indicates no expression detected.  
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1.C. CURRENT EVIDENCE ON ORGANIC CATION TRANSPORTER-
MEDIATED NEUROTRANSMITTER DISPOSTION IN BRAIN  
Depressive disorders is one of the most burdensome psychiatric disorders in the 
world. People who suffer from depression showed poor worker productivity and loss of 
interest in activities or hobbies. In addition, depression carries a high risk of suicide. 
Previous studies have demonstrated that the level of neurotransmitter  5-HT is decreased 
in the patients with depressive disorders [90]. As a consequence, understanding the 
mechanism of 5-HT clearance in brain is critical for designing and developing 
antidepressant drugs. There are two distinguishable mechanisms of aminergic 
neurotransmitter clearance from the synapse: uptake-1 (high-affinity, low capacity 
reuptake) and uptake-2 (low-affinity, high capacity reuptake) [91, 92]. Uptake-1 comprised 
the serotonin transporter (SERT; SLC6A4), norepinephrine transporter (NET; SLC6A2), 
and dopamine transporter (DAT; SLC6A3) (Figure 1.2) [91, 92]. Uptake-2 is proposed to 
play a backup role in monoamine neurotransmitter clearance [14]. The uptake-1 has been 
well characterized and a variety of antidepressant drugs, known as serotonin transporter 
reuptake inhibitors (SSRIs, e.g., fluoxetine and sertraline) and serotonin and 
norepinephrine transporter reuptake inhibitors (SNRIs, e.g., venlafaxine), have been 
developed to block SERT- and/or NET-mediated neurotransmitter uptake from the 
extracellular space. Uptake-2 has been gradually gaining attention as a new therapeutic 
target for antidepressant drugs. Over the last decade, much evidence has suggested that 
uptake 2 transporters are, at least partially, OCTs, specifically OCT2/Oct2 and OCT3/Oct3 
(Figure 1.2). Compared with OCT1/Oct1, OCT2/Oct2 and OCT3/Oct3 are widely 
distributed throughout brain [80, 81, 83, 87-89]. Several neurotransmitters, including 5-
HT, NE and DA, are known substrates of OCTs [93]. in 1996, Busch et al measured the 
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transport of monoamine neurotransmitters mediated by rOct1, and it was found that rOct1 
showed low affinity (high Km) but high capacity (maximum uptake rate) for 5-HT 
compared with SERT [74]. Further studies have been conducted to explore the impact of 
OCTs in depression, using OCT inhibitors or knockout mice. In 2005, Feng and co-workers 
observed a dose-dependent increase of 5-HT when perfusing decynium-22 (D-22), an 
inhibitor of OCTs, via a dialysis probe, that correlated with increased grooming, indicating 
that Octs might be an important regulatory element in adaptive neurophysiological and 
behavioral responses [94]. Interestingly, the magnitude of extracellular 5-HT concentration 
increased (~2-6 fold increase) by OCT inhibition was comparable to another study in which 
a 4 fold increase of extracellular 5-HT concentration was observed after SERT blockade 
by fluoxetine [94, 95]. Similarly, perfusing corticosterone (OCT inhibitor) into the medial 
hypothalamus potentiated the effect of fenfluramine on blocking the uptake of extracellular 
5-HT [94]. Administration of another OCT inhibitor, normetanephrine, in mice also 
increased extracellular NE in brain and produced enhanced antidepressant-like effects [96]. 
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Figure 1.2 Expression of the examined OCTs (SLC22 family) in the neurons and glial cells 
in the CNS.  
OCT: organic cation transporter; SERT: serotonin transporter; DAT: dopamine transporter; NET: 
norepinephrine transporter; concentrations indicated are for serotonin [97, 98].    
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Several studies have been conducted to investigate Oct expression in SERT knockout mice 
[99-101]. Notably, Oct3 mRNA expression in SERT knockout mice was significantly increased in 
hippocampus, but not in the cortex, striatum, cerebellum or brainstem, while Oct1 mRNA 
expression remained unchanged [100, 101]. Oct3 protein expression, measured by 
immunohistochemistry in the hippocampus was increased by 28% in SERT knockout mice [101]. 
Indeed, antidepressant-like effects (reflected in tail suspension test) in SERT mutant mice were 
observed when D-22 was administrated [101]. Similarly, another study demonstrated that Oct3 
expression was decreased by ~30% after seven day infusion of antisense mOct3 oligonucleotides 
in the third ventricle of adult mice brain [102]. And the mice also exhibited antidepressant-like 
effect correlated with loss of Oct3 activity, including enhanced locomotor response to 
methamphetamine, decreased immobility during the forced swim test, and a potentiated 
antidepressant response to imipramine [102]. These data indicated that OCT3/Oct3 might serve as 
a compensatory mechanism in response to dysfunctional 5-HT clearance. 
In a recent study, Horton et al. investigated the effect of D-22 on 5-HT clearance in the 
synapse and associated antidepressant-like activity in mice, when coadministered with 
fluvoxamine [103]. Clearly, D-22 coadministered with fluvoxamine increased the concentration 
of 5-HT in brain and caused increased antidepressant-like activity compared to those using 
fluvoxamine alone, indicating that Oct3 might be a novel target for antidepressant drugs [103]. 
The role of Oct2 in 5-HT clearance was investigated in Oct2 knockout mice [77]. A marked 
reduction in brain concentrations of NE and 5-HT, and in ex vivo uptake of both these 
neurotransmitters, were observed in Oct2 knockout mice in the presence of venlafaxine (an SNRI) 
[77]. As a consequence, markedly increased immobility time was observed in both forced swim 
and tail suspension tests, indicating an increased depressive-like phenotype [77]. In addition, 
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compared with wild-type mice, Oct2 knockout mice showed increased sensitivity to the acute 
administration of antidepressants [77]. Collectively, these data indicated an active role of 
OCT2/Oct2 in mediating NE and 5-HT clearance in brain. Thus, both in vitro and in vivo studies 
indicated that OCTs might be an important determinant of CNS monoamine neurotransmitter 
balance, and therefore play an important role in mood-related behaviors, elevating their potential 
as novel pharmacological targets for mood disorder therapy.   
1.D ORGANIC CATION AND ANION TRANSPORTER-MEDIATED DRUG 
INTERACTION 
Drug transporters are widely involved in drug absorption, distribution and elimination 
[104]. OCT1 has been recognized as a major transporter dominating the hepatic uptake of 
metformin, and genetic variation in OCT1 showed significant impact on 
metformin pharmacokinetics [105]. Several OATs, including OAT1, OAT3 and OAT4, are 
expressed in renal proximal tubular cells and manipulate active renal secretion and reabsorption 
[2]. As drug transporters influence the pharmacokinetics of a broad variety of therapeutics, it is 
expected that drug pharmacokinetic properties (e.g. AUC, clearance, and tissue distribution) and 
pharmacodynamic response might be altered due to concomitant administration of drugs that are 
substrates or inhibitors of the same transporter during situations of polypharmacy. This 
phenomenon is called drug-drug interactions (DDI), in which patients may experience unexpected 
side effects, such as loss of efficacy or toxicity. For instance, a clinical study demonstrated that 
systemic and peak exposure of  rosuvastatin was significantly increased in transplant recipients 
using cyclosporine, with AUC and Cmax increased by ~7 fold and ~11 fold compared with those 
using rosuvastatin [106]. Such DDIs might be caused by cyclosporine inhibition of OATP1B1-
mediated rosuvastatin hepatic uptake, and increased systemic exposure of rosvustatin showed high 
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risk of rosvustatin-related toxicity. Therefore, the United States Food and Drug Administration 
and the European Medicines Agency has issued guidance documents regarding circumstances 
under which drug interactions with specified transporters need to be investigated 
(http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM292362.pdf and http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/ 
document_detail.jsp?webContentId=WC500090112&murl=menus/document_library/document_
library.jsp&mid=WC0b01ac058009a3dc&jsenabled=true) for drug safety and efficacy. 
As mentioned in section 1.B, OCTs and OATs are widely expressed in many organs and 
in vivo mediate the absorption, distribution, and disposition of a broad variety of charged 
endogenous and exogenous organic substances [2, 3, 6]. Currently, hundreds of important clinical 
therapeutics have been identified as substrates and/or inhibitors of OCTs and OATs[16, 20]. For 
example, methotrexate, a commonly used drug for the treatment of cancer and rheumatic diseases, 
was identified as an OAT3/Oat3 substrate [107]. In Oat3 knockout mice, increase plasma 
concentration of methotrexate and methotrexate-to-inulin clearance were observed as compared to 
those in wildtype mice, indicating a role of Oat3 in the renal elimination of methotrexate [107]. 
Some fluoroquinolone antimicrobials, such as ciprofloxacin, gatifloxacin, and norfloxacin, 
showed significant inhibition on hOCT1, indicating that hOCT1 may play a role in the hepatic and 
renal disposition of these antimicrobial agents [108]. The antiviral lamivudine was identified as a 
substrate of hOCT2 [109]. As lamivudine is cleared predominantly by the kidney via renal tubular 
secretion, concomitant administration of drugs that inhibit hOCT2 could decrease its renal 
clearance. The antiplatelet drug clopidogrel and its major metabolite clopidogrel carboxylate 
showed potent inhibition of hOCT1 (IC50 values: 0.307–14.0 μM) [110]. Ethambutol, an anti-
tuberculosis drug, showed significant inhibitory effect on hOCT1, hOCT2, and hOCT3 [111]. 
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Considering the clinically unbound plasma concentration of ethambutol, tuberculosis patients with 
coexisting HIV or diabetes may experience DDIs with coadministration of ethambutol and drugs 
known to be hOCT1/hOCT3 substrates (e.g. lamivudine or metformin) [111]. Interestingly, some 
research groups have been starting to investigate the interaction of natural products and OCTs. Pan 
et al. reported that the alkaloids matrine and oxymatrine, which are widely used in China as herbal 
medicine for the treatment of cancer, viral, and cardiac diseases, showed inhibitory effects on 
hOCTs [112]. Additionally, berberine, known as an active constituent of many medicinal herbal 
extracts was identified as a potent inhibitor of hOCT2 and hOCT3, with IC50 values in the low 
micromolar range (0.1-1 µM) [113]. Such increased understanding of the vital roles SLC22 
transporters play in the absorption, distribution, elimination and reabsorption of drugs and 
endogenous compounds will serve to facilitate the development of drugs with increased specificity, 
safety and favorable pharmacokinetic profiles, as well as broaden our understanding of their roles 
in various pathophysiologies.   
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CHAPTER 2 
 
 
RESEARCH OBJECTIVES AND SPECIFIC AIMS 
 
 
 
 
2.A RESEARCH OBJECTIVES   
2.A.1 Many components in clinical therapeutics, herbal products, and drugs of abuse are charged 
at physiological pH and therefore represent unidentified substrates/inhibitors of organic cation 
(OCTs) or anion transporters (OATs).       
2.A.2 OCTs/OATs are sites of drug-drug interaction (DDI) during situations of polypharmacy and 
the DDI index, estimated based on the affinity (Ki and IC50) and clinical unbound plasma 
concentrations, can be used to predict clinically relevant DDIs potentially mediated by compounds 
confirmed to interact with SLC22 transporters in SA1.   
2.A.3. OCTs, as an important component of the low-affinity, high capacity clearance pathway 
(uptake-2) for biogenic monoamine neurotransmitters, represent novel targets for psychostimulant 
drugs of abuse and antidepressants.  
2.A.4. Construction of a hOCT3 homology model based upon the solved structure of the 
Piriformospora indica phosphate transporter (PiPT, PDB id 4J05) will allow identification of key 
transporter structural features required for substrate/inhibitor interactions. 
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2.B SPECIFIC AIMS TO ADDRESS THE ABOVE HYPOTHESES  
SPECIFIC AIM 1:  
To quantify the inhibitory effects on OCTs/Octs (hOCT1-3 and mOct1-3) or OATs (hOAT1, 
hOAT3 and hOAT4) of 5 constituents from therapeutic agents/herbal products, 5 drugs of abuse 
and 13 novel synthesized compounds having been identified as possessing physicochemical 
properties similar to known SLC22 family substrates and inhibitors.  
SPECIFIC AIM 2:   
To quantify IC50 or Ki values for lead compounds identified in SA1 as producing significant OCT 
or OAT inhibition based upon predefined conditions and to use this information to calculate DDI 
indices to determine the potential for clinically relevant DDIs mediated by OCTs/OATs based on 
“Guidance for Industry: Drug Interaction Studies” issued by the FDA. 
SPECIFIC AIM 3:   
To conduct in vivo dose response studies in mice to quantify (i.e., ED50 assessment) the 
antidepressant-like effects of lead quinazoline and/or guanidine compounds identified in SA1 and 
SA2 as having significant interaction potential on SLC22 transporters. 
SPECIFIC AIM 4:  
To construct a 3-D homology model for hOCT3 and dock known substrates and lead quinazoline 
and/or guanidine compounds identified in SA1 and SA2 in order to identify key amino acid 
residues that might be involved in interaction between hOCT3 and small molecules (done in 
collaboration with Dr. Dukat’s laboratory and Kavita Iyer). To determine the mode of inhibition 
of docked compounds to support modeling and docking study conclusions.  
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CHAPTER 3  
 
 
THE ANTHRAQUINONE DRUG RHEIN POTENTLY INTERFERES WITH ORGANIC 
ANION TRANSPORTER-MEDIATED RENAL ELIMINATION 
 
 
Drawn from manuscript published in Biochemical Pharmacology. 2013, 86: 991–996. 
 
 
 
 
3.A INTRODUCTION 
Great insight has been gained from in vitro and in vivo studies on drug transporters 
regarding their role in physiology and biopharmaceutics [104]. These drug transporters are 
expressed in barrier organs and involved in the interchange (e.g. uptake or removal) of endogenous 
and exogenous substances between cells and biofluids. Among these transporters, organic anion 
transporters (OATs), which belong to the SLC22 family, interact with anionic compounds [2, 6]. 
Three human (h) OAT paralogs, hOAT1, hOAT3, and hOAT4 have been identified as 
determinants for tubular secretion and reabsorption [2, 6]. Human OAT1 and hOAT3, 
immunolocalized to the basolateral side of proximal tubules, mediate cellular uptake of negatively 
charged organic molecules from the blood [2, 6]. Human OAT4, which is expressed on the apical 
side of proximal tubules, appears to mediate reabsorption of organic anions from tubular fluid [2, 
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6]. Such OAT-mediated organic solute flux is vital for maintaining systemic homeostasis and 
normal renal elimination. 
Numerous first-line therapeutics (e.g., antibiotics, ACE inhibitors and NSAIDs) and 
components of herbal medicines have been identified as substrates and/or inhibitors for OATs [2, 
6]. These findings demonstrate the impact of OATs on the pharmacokinetic properties of these 
drugs and provide efficacy and safety information for their clinical application. Interestingly, Oat3 
function has been linked to the regulation of blood pressure in mice. Oat3 knockout mice, and 
wild-type mice treated with potent Oat3 inhibitors, exhibited significantly reduced blood pressure 
compared to untreated wild-type animals [114]. For diabetic patients, blood pressure is a major 
determinant of the risk of developing nephropathy [115]. Thus, impairment of OAT function 
(either through genetics or pharmacology) may influence normal physiological status and result in 
unexpected drug-drug interactions (DDIs). 
The anthraquinone compound rhein is a major component of the medicinal herb Rheum sp., 
which is widely used for its antidotal, anti-inflammatory, antipyretic and laxative properties in 
Asian countries including China, Korea, and Japan. This medicinal herb is also used to treat 
diabetic nephropathy [116]. Further, rhein was identified as a major metabolite of diacerein, a 
prodrug used in the treatment of osteoarthritis [117]. In vivo, diacerein is completely converted to 
rhein before entering the systemic circulation [118, 119]. Rhein is highly protein bound in human 
plasma (99%) and, after oral administration, the majority of rhein is eliminated in urine as 
glucuronide conjugates (60%), followed by unchanged form (20%) and sulfate conjugates (20%) 
[118]. In clinical practice diacerein is utilized in polypharmacy therapies, e.g., a fixed dose of 
diacerein (50 mg) and aceclofenac (100 mg) has been approved in India to treat osteoarthritis [120]. 
Recently, a phase II clinical trial was initiated in Thailand to investigate the safety and efficacy of 
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the combined therapy of diacerein and methotrexate to treat early rheumatoid arthritis 
(http://clinicaltrials.gov/ct2/show/NCT01264211). As methotrexate and a number of NSAIDs are 
known inhibitors and substrates of OATs [2, 6], the interaction of rhein with OAT family members 
needs to be investigated in order to meaningfully assess the potential for transporter-mediated 
adverse events. 
Based on its chemical structure, rhein, which bears a carboxylic group, has the potential to 
be a substrate and/or inhibitor for OATs. Because OATs have broad substrate specificity, rhein 
may cause DDIs with co-administered therapeutics that are OAT substrates. This information may 
also be useful to elucidate the beneficial effects of Rheum sp. on diabetic nephropathy. In the 
present study, inhibition of hOAT1-mediated p-aminohippuric acid (PAH) transport and hOAT3- 
and hOAT4-mediated estrone sulfate (ES) transport by rhein was explored using stably transfected 
cell lines. Further kinetic studies were conducted to estimate the half maximal inhibitory 
concentration (IC50) and inhibitory constant (Ki). In order to investigate potential species 
differences IC50 and Ki estimates also were determined in murine (m) Oat1 and mOat3 expressing 
cells. The results showed that rhein was a potent inhibitor for hOAT1, hOAT3, and hOAT4. The 
IC50 values for rhein on hOAT1 and hOAT3 were estimated as 77.1 ± 5.5 nM and 8.4 ± 2.5 nM, 
respectively. However, rhein failed to produce > 50% inhibition on hOAT4 transport activity at 
100 µM, indicating that the IC50 value on hOAT4 was higher than 100 µM. Comparison of 
estimated IC50 values with clinical unbound plasma concentrations indicated the potential for 
clinically relevant DDIs on hOAT1 and hOAT3 in the kidney. In addition, marked species 
differences appeared to exist in inhibitory potency, with hOAT1 and hOAT3 exhibiting 3- and 28-
fold higher affinity with rhein as compared to their murine orthologs, respectively. Together, these 
findings suggested that rhein could interfere with hOAT1- and hOAT3-mediated renal elimination 
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in vivo, leading to unintended changes in pharmacokinetics, pharmacodynamics, toxicity and the 
therapeutic effects of Rheum sp.  
 
3.B Materials and Methods 
3.B.1 Chemicals  
Rhein (≥ 98% purity) was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, 
CA). Tritiated p-aminohippuric acid ([3H]PAH) and estrone sulfate ([3H]ES) were purchased from 
PerkinElmer Life and Analytical Sciences (Waltham, MA) and unlabeled PAH, ES, and 
probenecid were purchased from Sigma-Aldrich (St. Louis, MO). 
3.B.2 Tissue culture  
Derivation of stably transfected Chinese hamster ovary (CHO) cells expressing hOAT1 
(CHO-hOAT1), hOAT4 (CHO-hOAT4), mOat1 (CHO-mOat1), and mOat3 (CHO-mOat3) as well 
as stably transfected human embryonic kidney 293 (HEK) cells expressing hOAT3 (HEK-hOAT3), 
and their corresponding empty vector transfected background control cell lines, has been described 
previously [107, 121, 122]. All cells lines were maintained at 37C with 5% CO2 in medium 
containing 10% FBS and 1% Pen/Strep. CHO-hOAT1 cells were cultured in phenol red-free RPMI 
1640 media (Gibco-Invitrogen, Grand Island, NY) containing 1 mg/mL G418. CHO-hOAT4 cells 
were cultured in EMEM Alpha Modification media (Sigma-Aldrich (St. Louis, MO) containing 
0.5 mg/mL G418. CHO-mOat1 and CHO-mOat3 cells were cultured in DMEM F-12 media 
(Mediatech, Inc., Herndon, VA) containing 125 μg/mL hygromycin B. HEK cell lines were 
cultured in DMEM high glucose media (Mediatech, Inc., Herndon, VA) containing 125 µg/ml 
hygromycin B. 
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3.B.3 Cellular uptake assay 
The procedure for the cellular uptake assay was adapted from that previously published 
[123]. Two days before cellular uptake experiment, 2 × 105 cells/well were seeded in 24-well tissue 
culture plates and grown in the absence of antibiotics. On the day of the experiment, cells were 
equilibrated in transport buffer at room temperature (22-25C) for 10 min [500 µL of Hanks’ 
balanced salt solution containing 10 mM HEPES, pH 7.4]. After equilibration, this solution was 
replaced with 500 µL of fresh transport buffer containing 1 µM [3H]PAH (0.5 µCi/mL) or [3H]ES 
(0.25 µCi/mL) with or without inhibitors. At the end of incubation, cells were quickly rinsed three 
times with ice-cold transport buffer. Then cells were lysed with 1N NaOH, neutralized with 1N 
HCl, and analyzed via liquid scintillation counting. The intracellular accumulation of tritiated 
substrates was reported as picomoles of substrate per milligram total protein. All uptake data were 
corrected for background accumulation in corresponding empty vector transfected control cells. 
Substrate concentrations and accumulation times used for kinetic analysis of hOAT1, hOAT3, 
mOat1, and mOat3 were determined previously [107, 121, 123, 124]. Kinetic calculations were 
performed using GraphPad Prism Software version 5.0 (GraphPad Software Inc., San Diego, CA). 
The half maximal inhibitory concentrations (IC50) and inhibitory constants (Ki) were calculated 
using nonlinear regression. Results were confirmed by repeating all experiments at least three 
times with triplicate wells for each data point in every experiment. 
3.B.4 Statistics 
Data are reported as mean  SD or mean  SEM as indicated. Raw cell line accumulation 
data are reported as mean  SEM. Statistical differences were assessed using one-way ANOVA 
followed by post-hoc analysis with Dunnett’s t-test (α = 0.05) except for statistical differences 
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between murine and human transporter Ki values which were assessed by two-tailed Student’s 
unpaired t-test.  
3.C Results 
3.C.1 Inhibitory effects of rhein on hOAT1-, hOAT3-, and hOAT4-mediated substrate uptake  
Markedly increased cellular accumulation of PAH (7.9  0.1 pmol mg protein-1 10 min-1) 
was observed in CHO-hOAT1 cells compared to that in the empty vector transfected background 
control cells (0.3  0.1 pmol mg protein-1 10 min-1), and this hOAT1-mediated cellular uptake was 
inhibited by probenecid at 1 mM (Figure 3.1A). Rhein was assessed for inhibitory effects on CHO-
hOAT1 transport activity at 100 µM (Figure 3.1A). Under this condition, rhein completely blocked 
PAH accumulation (> 99% inhibition) in CHO-hOAT1 cells. Dose-response studies, applying 
increasing concentrations of rhein (10-9 to 10-5 M), were performed to determine the IC50 value 
(Figure 3.1B and Table 3.1). The IC50 value for rhein on hOAT1 was estimated as 77.1 ± 5.5 nM. 
Previous studies demonstrated that the mode of inhibition of most identified OAT inhibitors was 
competitive [107, 124-128]. Thus, assuming competitive inhibition, the inhibition constant (Ki) 
was estimated as 71.5 ± 5.2 nM (Table 3.1).  
CHO-hOAT3 cells exhibited significantly increased accumulation of ES (6.5  0.2 pmol 
mg protein-1 10 min-1) compared to that in the empty vector transfected background control cells 
(2.2  0.3 pmol mg protein-1 10 min-1). Similar to probenecid (1 mM), rhein showed virtually 
complete inhibition of hOAT3-mediated ES uptake at 100 µM (Figure 3.2A). Accordingly, dose-
response studies (10-9 to 10-4 M) were conducted to estimate affinity of rhein for hOAT3. Rhein 
showed much higher affinity for hOAT3 than for hOAT1, with an IC50 value of 8.4 ± 2.5 nM 
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(Figure 3.2B and Table 3.1). Assuming competitive inhibition, the Ki was estimated as 7.7 ± 2.4 
nM (Table 3.1). 
 
 
 
Figure 3.1 Inhibition of hOAT1 by rhein. 
 
A: Inhibition of hOAT1-mediated PAH (1 µM) uptake by rhein (100 µM) was assessed at 10 
min. Values are mean ± SD of triplicate samples. ***denotes p < 0.001 as determined by one-
way ANOVA followed by Dunnett’s t-test. B: Dose-response curve for rhein on hOAT1. One 
minute uptake of PAH (1 µM) was measured in CHO-hOAT1 cells in the presence of increasing 
concentrations of rhein (10-9 to 10-5 M). The IC50 was estimated using non-linear regression and 
the “log(inhibitor) vs. response” model (GraphPad Prism). All data were corrected for non-
specific background measured in control cells. 
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Figure 3.2 Inhibition of hOAT3 by rhein.  
 
A: Inhibition of hOAT3-mediated ES (1 µM) uptake by rhein (100 µM) was assessed at 10 min. 
Values are mean ± SD of triplicate samples. ***denotes p < 0.001 as determined by one-way 
ANOVA followed by Dunnett’s t-test. B: Dose-response curve for rhein on hOAT3. One minute 
uptake of ES (1 µM) was measured in HEK-hOAT3 cells in the presence of increasing 
concentrations of rhein (10-9 to 10-4 M). The IC50 was estimated using non-linear regression and 
the “log(inhibitor) vs. response” model (GraphPad Prism). All data were corrected for non-
specific background measured in control cells. 
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Stably transfected hOAT4-expressing (CHO-hOAT4) cells showed higher accumulation 
of ES (~24 fold) relative to empty vector transfected background control cells (26.9  3.5 vs. 1.1 
 0.1 pmol/mg protein/10 min, respectively; Figure 3.3). This active transport underwent self-
inhibition (> 99% inhibition) by ES (1 mM). Rhein, however, showed modest inhibition (~29%) 
on hOAT4 transport activity at 100 µM. As this indicated that the IC50 value of rhein on hOAT4 
should be higher than 100 µM, no further kinetic studies were performed. 
 
 
 
 
 
 
Figure 3.3 Inhibition of hOAT4 by rhein.  
 
A: Inhibition of hOAT4-mediated ES (1 µM) uptake by rhein (100 µM) was assessed at 10 min. 
Values are mean ± SD of triplicate samples. **denotes p < 0.01 and ***denotes p < 0.001 as 
determined by one-way ANOVA followed by Dunnett’s t-test. 
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3.C.2 Inhibitory effects of rhein on mOat1- and mOat3-mediated substrate uptake  
CHO-mOat1 and CHO-mOat3 cells showed > 10-fold increased substrate uptake compared 
to that in the empty vector transfected background control cells. The intracellular accumulation of 
PAH was measured as 8.0  0.3 pmol mg protein-1 10 min-1 and 0.8  0.2 pmol mg protein-1 10 
min-1 in CHO-mOat1 and background control cells, respectively. Accumulation of ES was 
measured as 171  12 pmol mg protein-1 10 min-1 and 5.7  1.5 pmol mg protein-1 10 min-1 in CHO-
mOat3 and background control cells, respectively. As shown in Figures 3.4A and 3.5A, probenecid 
(1 mM) achieved complete inhibition (> 99% inhibition) of mOat1- and mOat3-mediated substrate 
uptake. At 100 µM, rhein exhibited potent inhibition, completely blocking mOat1 and mOat3 
transport activity (Figures 3.4A and 3.5A). Further dose-response studies (10-8 to 5×10-4 M) were 
performed to determine the IC50 values in order to evaluate potential species differences between 
human and murine OATs (Figures 3.4B and 3.5B and Table 3.1). The IC50 values were estimated 
as 215 ± 29 nM and 235 ± 74 nM for mOat1 and mOat3, respectively. Assuming that rhein was a 
competitive inhibitor, Ki values were estimated as 198 ± 26 nM and 216 ± 68 nM, respectively 
(Table 3.1). 
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Figure 3.4 Inhibition of mOat1 by rhein.  
 
A: Inhibition of mOat1-mediated PAH (1 µM) uptake by rhein (100 µM) was assessed at 10 min. 
Values are mean ± SD of triplicate samples. ***denotes p < 0.001 as determined by one-way 
ANOVA followed by Dunnett’s t-test. B: Dose-response curve for rhein on mOat1. One minute 
uptake of PAH (1 µM) was measured in CHO-mOat1 cells in the presence of increasing 
concentrations of rhein (10-8 to 5×10-4 M). The IC50 was estimated using non-linear regression 
and the “log(inhibitor) vs. response” model (GraphPad Prism). All data were corrected for non-
specific background measured in control cells. 
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Figure 3.5 Inhibition of mOat3 by rhein.  
 
A: Inhibition of mOat3-mediated ES (1 µM) uptake by rhein (100 µM) was assessed at 10 min. 
Values are mean ± SD of triplicate samples. ***denotes p < 0.001 as determined by one-way 
ANOVA followed by Dunnett’s t-test. B: Dose-response curve for rhein on mOat3. One minute 
uptake of ES (1 µM) was measured in CHO-mOat3 cells in the presence of increasing 
concentrations of rhein (10-8 to 5×10-4 M). The IC50 was estimated using non-linear regression 
and the “log(inhibitor) vs. response” model (GraphPad Prism). All data were corrected for non-
specific background measured in control cells. 
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Table 3.1 Estimated kinetic constants (IC50, Ki) and DDI indices for rhein on OATs. 
Transporter 
IC50 
(nM) 
Ki 
(nM)a 
Unbound 
 Cmax (nM)
b 
DDI index 
Ki ratio 
(murine/human) 
hOAT1 77.1 ± 5.5 71.5 ± 5.2 67-387 5.0  
hOAT3 8.4 ± 2.5 7.7 ± 2.4 67-387 46  
hOAT4 > 100, 000 > 100, 000    
mOat1 215 ± 29 198 ± 26   2.8** 
mOat3 235 ± 74 216 ± 68   28** 
Values are reported as mean ± SEM.  
a Ki values were estimated assuming competitive inhibition based on literature.   
b Clinical Cmax values were reported from literature.     
**denotes significant difference between murine and human Ki values p < 0.01 as determined by 
two-tailed Student’s unpaired t-test. 
 
3.D Discussion 
With increasing clinical evidence supporting drug transporter-mediated DDIs, it is 
necessary to identify potential substrates and inhibitors from both existing and new candidate drugs 
[104]. Hundreds of endogenous and exogenous compounds have been identified as substrates 
and/or inhibitors for OATs, including clinically important therapeutics such as antibiotics 
(benzylpenicillin, cephaloridine, cefdinir and cefotiam), antivirals (adefovir, cidofovir, and 
ganciclovir), anticancer agents (methotrexate), cholesterol-lowering agents (pravastatin), and 
angiotensin-converting enzyme inhibitors (quinapril) [2, 6]. Such broad substrate specificity 
markedly increases the risk of DDIs, especially during combination therapies. In addition, recent 
investigations demonstrated potential interaction between OATs and natural products, including 
phenolic acids, flavonoids, and other anionic compounds [123, 124]. While these natural products 
are major components of herbal medicines and nutritional supplements, information on the proper 
use and safety of these compounds is limited compared to “traditional” western drugs. Rhein is 
 
 
43 
 
both a major metabolite of the prodrug diacerein and a major constituent of the medicinal herb 
Rheum sp.  
In the present study, the inhibitory effects of rhein on three human OATs (hOAT1, hOAT3, 
and hOAT4) and two murine OAT orthologs (mOat1 and mOat3) were assessed. Rhein showed 
significant inhibition on substrate uptake mediated by hOAT1, hOAT3 and hOAT4 at 100 µM. 
Kinetic studies demonstrated that the estimated IC50 values for hOAT1 and hOAT3 were in the 
low nanomolar range (IC50 = 77.1 ± 5.5 nM and 8.4 ± 2.5 nM for hOAT1 and hOAT3, respectively), 
while hOAT4 showed poor affinity with rhein (IC50 > 100 µM). The estimated IC50 values for 
mOat1 and mOat3 were somewhat higher (IC50 = 215 ± 29 nM and 235 ± 74 nM for mOat1 and 
mOat3, respectively), indicating that human OATs exhibited higher affinity for rhein compared to 
their murine orthologs. In addition, rhein exhibited ~9-fold higher affinity (lower Ki value) for 
hOAT3 than for hOAT1, while no significant difference between mOat1 and mOat3 was observed 
(Table 3.1). 
For most identified OAT inhibitors, Ki values are in the micromolar range, with some 
compounds exhibiting much poorer affinity (Ki values > 1 mM) [2, 6]. Very few compounds have 
shown extremely high affinity (nM) for OATs, e.g., some cephalosporin antibiotics, ochratoxin A, 
prostaglandin E2 and prostaglandin F2α. In this study, the estimated IC50 and Ki values for hOAT1 
and hOAT3 were less than 100 nM, making rhein one of the most potent inhibitors yet identified 
for hOAT1 and hOAT3. Such high affinity indicates that rhein has the potential to interfere with 
hOAT1- and hOAT3-mediated renal elimination of endogenous, as well as xenobiotic, substances. 
The Food and Drug Administration guidance for industry, “Drug Interaction Studies — Study 
Design, Data Analysis, Implications for Dosing, and Labeling Recommendations” recommends 
that DDI potency be estimated using the DDI index, calculated as the [unbound] Cmax/Ki (or IC50) 
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ratio [129]. A DDI index value greater than 0.1 indicates that the test compound has the potential 
to perpetrate in vivo DDIs. Based on clinical reports, the range of Cmax of rhein was from 8.8 to 
14.8 µM after administration of a typical dose of diacerein (50 mg) [119, 120, 130], and the Cmax 
of rhein in patients administered Rheum sp. ranged from 6.7 to 38.7 µM [131-133], indicating 
similar peak exposure level. Although most rhein molecules in human plasma exist as the bound 
form (99%), the unbound Cmax (67-387 nM) of rhein is close to or higher than the IC50 values 
determined in this study. The maximum DDI index was calculated as 5.0 and 46 for hOAT1 and 
hOAT3, respectively. These results indicated significant inhibition potential on hOAT1 (83%) and 
hOAT3 (98%) transport activity, resulting in reduced hOAT1- and hOAT3-mediated renal tubular 
secretion of co-administered therapeutics that are OAT substrates. As mentioned earlier, diacerein 
is combined with NSAIDs or methotrexate in clinical applications for the treatment of 
osteoarthritis or rheumatoid arthritis. However, for herbal medicines containing Rheum sp. (rhein) 
there is no official warning regarding potential herb-drug interactions. Therefore, further in vivo 
pharmacokinetic studies are necessary to explore potential DDIs involving rhein.  
Animal models are commonly employed to demonstrate DDI potential in vivo. However, 
if notable species differences between the animal model and humans appear to exist, the utility of 
results from animal studies may be lacking. Currently, limited work has been done to demonstrate 
species differences in inhibitory potency on OATs. Some compounds (e.g., diclofenac and 
sulindac) showed preferential affinity with rodent OATs compared to human orthologs, while 
other substances (e.g., adefovir, cefoperazone, cephalothin, cidofovir and methotrexate) exhibited 
lower Ki or Km values for human OATs [6]. Previous work showed that hOAT1 exhibited 3.4-16 
fold higher affinity for three Danshen (a traditional Chinese herbal medicine) components, 
rosmarinic acid, salvianolic acid B and tanshinol, as compared to mOat1, and five Danshen 
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compounds (lithospermic acid, rosmarinic acid, salvianolic acid A, salvianolic acid B and 
tanshinol) exhibited much higher affinity (by 1-2 orders of magnitude) for hOAT3 over mOat3 
[124]. In the current study, rhein also exhibited higher affinity for hOAT1 and hOAT3, with 3- 
and 28-fold lower Ki values than those for mOat1 and mOat3. These differences raised the issue 
that DDI potency observed in mice at clinically relevant doses may underestimate the in vivo DDI 
potential for humans. Thus, the dose would need to be adjusted in order to balance the discrepancy 
in affinities between species. This highlights the significance of in vitro work to delineate species 
differences in affinity with OATs before using animal models to conduct pharmacokinetic studies 
and extrapolating the results to humans. Other animal models (e.g., dog or monkey) should be 
investigated more thoroughly with respect to OATs to determine if they represent a more 
appropriate animal model. 
Progression of diabetes mellitus sometimes results in diabetic nephropathy and renal failure 
[115]. Although the mechanism underlying the therapeutic effect of antihypertensive drugs is not 
well understood, clinically they are used to slow the onset of diabetic nephropathy and lower blood 
pressure [115]. In 2008, Vallon et al. reported that reduced blood pressure was observed in Oat3 
knockout mice and wild-type mice treated with potent Oat3 inhibitors [114]. These data suggested 
that hOAT3 might represent a novel target to ameliorate diabetic nephropathy. Similarly, the 
Danshen component, lithospermic acid, was demonstrated to significantly reduce blood pressure 
and to exert nephroprotective effects in diabetic rats [134, 135]. Though other mechanisms for 
attenuated diabetic nephropathy may exist, the potential contribution of reduction in blood pressure 
via inhibition of OAT3/Oat3 function by Danshen components such as lithospermic acid can not 
be ruled out [124]. A clinical investigation demonstrated that rhei rhizoma (the dried root and 
rhizome of Rheum sp.) also exhibited beneficial effects for diabetic nephropathy [116]. Thus, it is 
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possible that rhein might exert positive effects on diabetic nephropathy through inhibition of 
hOAT3 transport activity and subsequent downregulation of blood pressure. 
In summary, the anthraquinone drug rhein showed marked inhibition on hOAT1- and 
hOAT3-mediated substrate uptake at clinically relevant concentrations. Notable species 
differences were observed between human and murine OAT orthologs, with human OATs 
exhibiting preferential affinity. The DDI indices for rhein on hOAT1 and hOAT3 indicated a 
strong potential for OAT-mediated DDIs in patients involved in combination therapy of rhein and 
drugs that are known hOAT1 and/or hOAT3 substrates. Moreover, the nanomolar affinities of 
rhein for hOAT1 and hOAT3 mirror known OAT affinities for endogenous compounds, e.g., 
hormones, raising the possibility of significant drug-endogenous molecule interactions as well. 
Such a mechanism might explain the effects of rhein and lithospermic acid on blood pressure, i.e., 
via inhibiting the uptake of an endogenous hOAT3 substrate involved in regulation of blood 
pressure.  
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CHAPTER 4  
 
INTERACTION OF ETHAMBUTOL WITH HUMAN ORGANIC CATION 
TRANSPORTERS (SLC22 FAMILY) INDICATES POTENTIAL FOR DRUG-DRUG 
INTERACTIONS DURING ANTITUBERCULOSIS THERAPY  
 
Drawn from manuscript published in Antimicrob. Agents Chemother. 2013. 57(10): 5053-5059. 
 
 
 
 
4.A INTRODUCTION  
Ethambutol dihydrochloride (EMB) (Figure 4.1) is a potent antimycobacterial agent 
employed in the treatment of tuberculosis (TB) and Mycobacterium avium complex infections. 
The main pharmacological effect of EMB is to inhibit arabinosyl transferase, preventing the 
synthesis of arabinogalactan, which is a vital component of the mycobacterial cell wall. EMB, 
pyrazinamide, isoniazid, and rifampin comprise the four first-line antituberculosis drugs 
recommended by the World Health Organization (WHO) [136]. EMB is used in the treatment of 
multidrug-resistant tuberculosis to prevent the emergence of isoniazid- or rifampin-resistant 
mycobacteria [137]. In clinical practice, EMB use is associated with many adverse effects, 
including optic neuritis (reported in 1% to 5% of patients) [138] and reduced renal clearance of 
urate (reported in about 66% of patients) [139], the incidence of which is higher when EMB is 
concomitantly administered with pyrazinamide [140]. The in vivo pharmacokinetic properties of 
EMB have been well defined [141-143]. In humans, EMB showed high bioavailability (80%) and 
low plasma protein binding (20 to 30%) [144]. A peak serum concentration (Cmax) of 4.5g/ml was 
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reported after oral dosing of 25 mg/kg [141]. Only a small portion of EMB (8% to 15%) is 
metabolized in the liver to form the final dicarboxylic metabolite, 2,2’-(ethylenediimino)dibutyric 
acid (EDA) (Figure 4.1) [145]. Renal elimination is the major clearance mechanism for EMB, with 
70 to 84% of an intravenous dose being excreted in the urine as the unchanged parent compound 
[144]. The renal clearance rate (417 ml/min) indicates that active net tubular secretion, as well as 
glomerular filtration (120 ml/min), is involved [141]. While EMB has been identified as a substrate 
of P-glycoprotein [146], based upon their chemical structures (Figure 4.1) and physicochemical 
properties, EMB and EDA have the potential to be a substrate and/or inhibitor of OCTs and/or 
OATs. 
The organic cation/anion/zwitterion transporters belong to the solute carrier 22 (SLC22) 
family and in vivo mediate the absorption, distribution, and elimination of a broad variety of 
charged endogenous and exogenous organic substances [2, 3, 6]. OATs and OCTs are widely 
expressed in many barrier organs, such as the intestine, kidney, liver, and brain [2, 3, 6]. In the 
intestine (Figure 4.2), human OCT1 (hOCT1) (SLC22A1) is expressed in the basolateral 
membrane and hOCT3 (SLC22A3) is targeted to the brush border membrane of enterocytes, where 
they mediate the cellular entry of cationic compounds [3]. hOCT1 and hOCT3 are both expressed 
in the sinusoidal membrane (blood side) of hepatocytes (Figure 4.2) and represent the first step in 
the hepatic excretion of many substances [3, 147]. In the kidney (Figure 4.2), hOCT2 (SLC22A2), 
hOCT3, hOAT1 (SLC22A6), and hOAT3 (SLC22A8) are each expressed on the basolateral sides 
of proximal tubule cells and extract drugs from the blood. hOCT1 mRNA has been detected; 
however, the protein has not been immunolocalized [2, 3]. Hundreds of important clinical 
therapeutics are known substrates and/or inhibitors of OATs and OCTs, such as chemotherapeutics 
(e.g., cisplatin and paclitaxel), analgesics (e.g., morphine), cholesterol-lowering drugs (e.g., 
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atorvastatin and pravastatin), antivirals (e.g., cidofovir and lamivudine), and antidiabetic agents 
(e.g., metformin) [2, 3, 6].  
Recently, it was reported that TB infection is closely linked to both human 
immunodeficiency virus (HIV) and diabetes. According to the WHO, 10% of TB patients also 
suffer from diabetes and 13% of the 9 million TB patients newly diagnosed in 2011 were coinfected 
with HIV [136]. Thus, the complexity of these disease treatment regimens (TB, TB-diabetes, or 
TB-HIV), in terms of polypharmacy, raises concerns regarding the potential for drug-drug 
interactions (DDIs) involving OCTs and/or OATs. The aim of the present study was to explore the 
inhibitory effects of EMB and its metabolite EDA on hOCT1, hOCT2, hOCT3, hOAT1, and 
hOAT3. Potent inhibition was further characterized by kinetic investigations to estimate IC50s, 
which were used to quantitatively evaluate the clinical DDI potential on these transporters during 
antituberculosis therapy. 
4.B MATERIALS AND METHODS 
4.B.1 Chemicals  
Tritiated p-aminohippuric acid ([3H]PAH), estrone sulfate ([3H]ES), and 1-methyl-4-
phenylpyridinium ([3H]MPP+) were purchased from PerkinElmer Life and Analytical Science 
(Waltham, MA). Unlabeled ES, MPP+, PAH, probenecid, and ethambutol dihydrochloride (EMB, 
95% purity) were obtained from Sigma-Aldrich (St. Louis, MO). Quinine monohydrochloride 
dihydrate was purchased from Acros Organics (Fair Lawn, NJ). 2,2’-(Ethylenediimino)dibutyric 
acid (EDA; 99% purity) was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). 
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Figure 4.1. Chemical structures of ethambutol (EMB) and its dicarboxylic metabolite 2,2'- 
(ethylenediimino)dibutyric acid (EDA).  
 
MW, molecular mass. 
 
 
4.B.2 Tissue culture  
Derivation of stably transfected Chinese hamster ovary (CHO) cell lines expressing hOAT1 
(CHO-hOAT1) and stably transfected human embryonic kidney 293 (HEK) cells expressing 
hOAT3 (HEK-hOAT3), hOCT1 (HEK-hOCT1), hOCT2 (HEK-hOCT2), or hOCT3 (HEK-
hOCT3), as well as their corresponding empty vector-transfected background control cell lines, 
has been described previously [14, 107, 121, 148]. CHO-hOAT1 cells were maintained at 37°C 
with 5% CO2 in phenol red-free RPMI 1640 medium (Gibco-Invitrogen, Grand Island, NY) 
containing 10% serum, 1% penicillin/streptomycin, and 1 mg/ml G418. HEK-hOAT3 cells were 
maintained at 37°C with 5% CO2 in high glucose Dulbecco’s modified Eagle medium (DMEM; 
Mediatech, Inc., Herndon, VA) containing 10% serum, 1% penicillin/streptomycin, and 125 µg/ml 
hygromycin B. The HEK-hOCT1, HEK-hOCT2, and HEK-hOCT3 cell lines were maintained at 
 
 
51 
 
37°C with 5% CO2 in high-glucose DMEM containing 10% serum, 1% penicillin/streptomycin, 
and 600 µg/ml G418. 
4.B.3 Cell accumulation assays  
  The procedure for the cell accumulation assay has been described previously [123, 124]. 
Briefly, cells were seeded into 24-well tissue culture plates at a density of 2 × 105 cells/well 
(without antibiotics) for 48 h. On the day of the cell transport experiment, the cells were 
equilibrated to serum-free conditions with transport buffer for 10 min (500 µL of Hanks’ balanced 
salt solution containing 10 mM HEPES, pH 7.4). Equilibration buffer was replaced with 500 µL 
of fresh transport buffer containing 1 µM unlabeled substrate spiked with [3H]PAH (0.5 µCi/ml), 
[3H]ES (0.25 µCi/ml), or [3H]MPP+ (0.25 µCi/ml) in the presence or absence of test compounds. 
At the end of the incubation, the cells were quickly rinsed three times with ice-cold transport buffer 
and lysed. The radioactivity of cell lysate was quantified by liquid scintillation counting, and the 
uptake profile was normalized by the total protein content determined by the Bradford method. 
The intracellular accumulation of substrates was reported as picomoles of substrate per milligram 
total protein. All uptake data were corrected for background accumulation in corresponding empty 
vector-transfected control cells. Substrate concentration and accumulation time used for kinetic 
analyses were determined previously [3, 124]. Kinetic calculations were performed using 
GraphPad Prism software version 5.0 (GraphPad Software Inc., San Diego, CA). The half-
maximal inhibitory concentrations (IC50s) were calculated using nonlinear regression with the 
appropriate model. Results were confirmed by repeating all experiments at least three times with 
triplicate wells for each data point in every experiment. 
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4.B.4 Drug-drug interaction (DDI) index calculation  
The DDI index [104] was estimated as the ratio of the maximal unbound EMB 
concentration in biofluid (unbound Cmax) after therapeutic dosing of EMB divided by transporter-
specific IC50s estimated by in vitro assay. A cutoff value of ≥ 0.1 is thought to indicate the need for 
a prospective in vivo pharmacokinetic study [104]. Specifically, the predicted intestinal lumen 
concentration of EMB after oral dosing (25-mg/kg dose, 70-kg patient body weight, 250 ml 
volume) was used to estimate the DDI index for hOCT3 located in the apical (luminal) membranes 
of enterocytes, while the portal venous plasma concentration (presystemic circulation) of EMB 
was used to estimate DDI index values for hOCTs in the basolateral membranes of hepatocytes 
(hOCT1 and hOCT3) and/or enterocytes (hOCT1 and hOCT2), and the plasma concentration 
(systemic circulation) of EMB was used to estimate DDI index values for hOCT1, hOCT2, and 
hOCT3 in the basolateral membranes of renal proximal tubule cells (Figure 4.2). The concentration 
of EMB in the intestinal lumen was estimated to be ~34 mM, assuming that patients (70 kg) take 
EMB with 250 ml of water. From clinical reports, after oral dosing (25 mg/kg) the plasma Cmax of 
EMB was 22.02 µM, with about 20% being protein bound [141, 144, 149]. Accordingly, the 
method of Ito et al. can be used to estimate drug concentrations in the portal vein [150]: Cport,vn = 
Cmax + (ka × D)/(Qh × Fa), where Cport,vn, ka, D, Qh, and Fa represent concentration in the portal vein, 
absorption rate constant, dose, hepatic blood flow rate (~1,200 ml/min), and fraction absorbed, 
respectively. For EMB, ka and Fa were reported as 0.48 h
-1 and 80% [144, 149]. Using an average 
patient body weight of 70 kg, the predicted portal venous blood concentration for EMB was ~67 
µM.  
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4.B.5 Statistical analysis  
The data in the figures and the raw uptake scores are expressed as means ± standard 
deviations (SD), while IC50 estimates are means ± standard errors of the means (SEM). Statistical 
differences were assessed using one-way analysis of variance (ANOVA) followed by post hoc 
analysis with Dunnett’s t test (α = 0.05).
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Figure 4.2 Illustration relating expression of the examined human OCTs and OATs (SLC22 
family) in the intestine, liver and kidney.  
 
Predicted (GI lumen and portal circulation) and clinically determined (systemic circulation) 
concentrations of EMB are indicated. Renal expression and targeting of hOCT1 remains 
controversial, with conflicting reports about its location in the literature, however, the rat Oct1 
ortholog has been immunolocalized to the basolateral membrane of proximal tubule cells. 
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4.C RESULTS 
4.C.1 Inhibitory effects of EMB on hOCT1-, hOCT2-, and hOCT3-mediated MPP+ uptake 
 The inhibitory effects of EMB were examined on three OCT paralogs, hOCT1, hOCT2, 
and hOCT3, using MPP+ as a prototypical substrate. Significant accumulation of MPP+ (~33-fold) 
was observed in stably transfected hOCT1-expressing cells relative to empty-vector-transfected 
background control cells (132.6 ± 9.9 versus 4.0 ± 0.2 pmol/mg protein/10 min, respectively). The 
known hOCT inhibitor, quinine (200 µM), showed virtually complete inhibition of hOCT1-
mediated MPP+ uptake (>90% inhibition) (Figure 4.3A). Significant inhibition (66%) of hOCT1-
mediated MPP+ transport by EMB (at 100 µM versus 1 µM MPP+) was observed (Figure 4.3A). 
Subsequent dose-response (10-7 to 10-3 M EMB) studies were performed to derive the IC50 for 
EMB on hOCT1 (Figure 4.4, top). The IC50 of EMB for hOCT1 was estimated as 92.6 ± 10.9 µM. 
Therefore, the DDI indices were calculated to gauge DDI potency in enterocytes, hepatocytes, and 
proximal tubule cells, using the EMB concentration in gastrointestinal (GI) biofluid, portal venous 
blood, or the systemic circulation, as appropriate (Figure 4.2 and Table 4.1). 
We next examined the inhibitory effect of EMB on hOCT2-mediated transport. HEK-
hOCT2 cells exhibited marked accumulation of MPP+ (93.0 ± 5.2 pmol/mg protein/10 min) 
compared to background control cells (4.0 ± 0.2 pmol/mg protein/10 min). Quinine (200 µM) 
completely blocked (>99%) hOCT2-mediated MPP+ uptake (Figure 4.3B). The cell accumulation 
assay demonstrated that EMB at 100 µM significantly inhibited hOCT2-mediated MPP+ uptake 
(21%), and complete inhibition of hOCT2 transport activity (96%) was observed at 1 mM EMB. 
Kinetic studies were conducted to estimate the IC50 for EMB on hOCT2. Using EMB 
concentrations ranging from 10-6 to 10-3 M, the IC50 was estimated as 253.8 ± 90.8 µM (Figure 4.4, 
 
 
56 
 
middle). As shown in Table 4.1, the DDI index for hOCT2 expressed in kidney was estimated as 
0.1. 
 Stably transfected hOCT3-expressing (HEK-hOCT3) cells also showed marked 
accumulation of MPP+ (~30-fold) compared to empty vector-transfected background control cells 
(80.3 ± 11.3 versus 2.7 ± 0.1 pmol/mg protein/10 min). Such active transport was completely (99%) 
blocked by quinine at 200 µM (Figure 4.3C). Though EMB failed to show significant inhibition 
on hOCT3 transport activity at 100 µM, marked inhibition was observed with increasing 
concentrations (Figure 4.3C). EMB showed ~50% and ~80% inhibition at 1 and 10 mM, 
respectively. Further dose-response (10-3 to 10-1 M EMB) studies yielded an estimated IC50  of 4.1 
± 1.6mM (Figure 4.4, middle). Due to low EMB concentration in the presystemic (portal) and 
systemic circulation, DDI indices for hOCT3 in liver and kidney were negligible compared to the 
0.1 threshold value (Table 4.1). However, the high concentration of EMB in the GI biofluid yielded 
an estimated DDI index around 8.3.  
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Figure 4.3. Inhibition profiles of EMB on hOCT1, hOCT2 and hOCT3. 
 
A: Inhibition of hOCT1-mediated MPP+ uptake by EMB and quinine (200 μM). B: Inhibition of 
hOCT2-mediated MPP+ uptake by EMB and quinine (200 μM). C: Inhibition of hOCT3-mediated 
MPP+ uptake by EMB and quinine (200 μM). The concentration of MPP+ was 1 μM, incubation 
time was 10 min, and data shown were corrected for non-specific background. Values are mean ± 
SD of triplicate values. *** denotes p < 0.001 as determined by one-way ANOVA followed by 
Dunnett’s t-test. 
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Figure 4.4. Dose-response curves for EMB on hOCT1, hOCT2 and hOCT3. 
 
Representative data showing 1 min uptake of MPP+ (1 µM) measured in HEK-hOCT1, HEK-
hOCT2, and HEK-hOCT3 cells in the presence of increasing concentrations of EMB (10-7 to 10-1 
M) are shown. Data were corrected for nonspecific background measured in the empty vector 
control cells and are means ± SD of triplicate values. IC50s were determined with nonlinear 
regression and the “log(inhibitor) versus response” model using GraphPad Prism software. 
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4.C.2 Inhibitory effects of EDA on hOAT (hOAT1andhOAT3) and hOCT (hOCT1, hOCT2, and 
hOCT3) transport activity  
The zwitterionic dicarboxylic acid metabolite of EMB, EDA, was examined for 
interactions with hOAT1, hOAT3, hOCT1, hOCT2, and hOCT3 (Figure 4.5). The standard 
substrate used for hOAT1 was PAH, and that for hOAT3 was ES. Stably transfected hOAT1-
expressing (CHO-hOAT1) and hOAT3-expressing (HEKhOAT3) cells showed 5-fold- and 3-fold-
greater substrate accumulation than empty-vector-transfected background control cells, 
respectively (7.5 ± 1.6 versus 1.6 ± 0.2 pmol/mg protein/10 min for hOAT1 and 4.1 ± 0.2 versus 
1.6 ± 0.1 pmol/mg protein/ 10 min for hOAT3). The known OAT inhibitor probenecid completely 
blocked (>99%) hOAT1- and hOAT3-mediated substrate uptake (Figure 4.5). With the exception 
of hOAT3 (~17% inhibition), EDA (100 µM) failed to produce any significant inhibitory effects. 
Despite the modest inhibition of hOAT3, for all tested transporters IC50s of EDA were expected to 
be greater than 100 µM, which greatly exceeds the EDA concentration in the systemic circulation, 
and further kinetic analysis was not performed.  
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Figure 4.5 Inhibition profile of EDA on hOATs and hOCTs.  
 
(A) Inhibition of hOAT1-mediated PAH uptake by EDA (100 µM) and probenecid (1,000 µM).  
(B) Inhibition of hOAT3-mediated ES uptake by EDA (100 µM) and probenecid (1,000 µM).  
(C) Inhibition of hOCT1-mediated MPP+ uptake by EDA (100 µM) and quinine (200 µM).  
(D) Inhibition of hOCT2-mediated MPP+ uptake by EDA (100 µM) and quinine (200 µM).  
(E) Inhibition of hOCT3-mediated MPP+ uptake by EDA (100 µM) and quinine (200 µM).  
The concentration of substrates was 1 µM, incubation time was 15 min, and data were corrected 
for nonspecific background. Values are means ± SD of triplicate values. ***, P < 0.001, determined 
by one-way ANOVA followed by Dunnett’s t test. 
 
 
 
Table 4.1 Estimated DDI index values for EMB on hOCT-mediated transport after an oral 
dose of 25 mg/kg.   
 
 Drug-drug interaction indexa 
hOCT GI tract Liver Kidney 
hOCT1 0.6 0.6 0.2b 
hOCT2 NEc NE 0.1 
hOCT3 8.3 < 0.1 < 0.1 
a Drug-drug interaction index is defined as the unbound concentration of drug divided by the 
drug IC50 for the transporter of interest. A DDI index value of  >0.1 is thought to indicate the 
potential for clinically relevant DDIs. 
b Assuming basolateral targeting for hOCT1. 
c NE, transporter not expressed in this tissue. 
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4.D DISCUSSION 
Although numerous antitubercular drugs have been developed since the 1940s, TB is still 
a prevalent disease and a common cause of death worldwide. Recently, the spread of multidrug-
resistant TB strains (MDR-TB; estimated to account for 3.7% of new cases and 20% of previously 
treated cases) and the emergence of an extensively drug-resistant strain (XDR-TB; ~9% of MDR-
TB cases) that has proven virtually impossible to successfully treat have become new challenges 
to disease management [136, 151]. The appearance of XDR-TB has been reported in 84 countries, 
and the threat of its spread is viewed as a significant enough health issue that the United Kingdom 
has enacted regulations obligating people traveling from regions where TB is prevalent to have a 
current chest X-ray in their possession upon arrival in order to be issued a visa [152]. Isolation and 
therapy may be required for up to 2 years and can cost upwards of one million U.S. dollars per 
patient [152]. 
A further complication in TB therapy arises from the increasing clinical association of TB 
with diabetes and HIV, with TB becoming one of the leading causes of mortality among HIV 
infected patients [153, 154]. Indeed, of the ~9 million new TB patients diagnosed in 2011, 13% 
were reported to be coinfected with HIV, and of the 1.4 million TB deaths, 430,000 were HIV 
associated [136]. As a result, more TB patients need to be prescribed combination therapies to treat 
comorbidities or to minimize the development of drug resistance, making therapy management 
and compliance extremely complex and increasing the risk of patients’ experiencing unintended 
drug-drug interactions. Indeed, there are a number of case reports regarding adverse events, 
including nephrotoxicity, associated with EMB use during antituberculosis therapy [155-158]. In 
these patients, discontinuation of EMB resulted in improvement in renal function. 
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Competition for binding to membrane transporters is one mechanism resulting in DDIs, 
and while there is currently insufficient clinical data to conclusively determine transporter-
mediated DDI involvement, it is possible that hOCT-mediated DDIs explain some of these cases. 
As such, potential interactions between antituberculosis agents and drug transporters have received 
increased attention. For example, rifampin was identified as an inhibitor of P-glycoprotein 
(ABCB1), OATP1B1 (SLCO1B1), and OAPT1B3 (SLCO1B3), whereas pyrazinamide was 
demonstrated to inhibit hURAT1 (SLC22A12) [159-161]. EMB also was reported as a substrate 
for P-glycoprotein [146]; however, information regarding potential interactions with other drug 
transporters, especially drug uptake transporters, is virtually nonexistent. Additionally, many anti-
diabetic (metformin) and anti-HIV (lamivudine, raltegravir, tenofovir, and zalcitabine) agents have 
been identified as substrates and/or inhibitors of OCTs and OATs [2, 3, 6, 162-164]. Therefore, in 
order to more effectively and safely manage the longterm therapies of these complicated patient 
populations, improved understanding of the interactions of these drugs with the transporters 
responsible for their absorption, distribution, and elimination is needed. 
 A number of preclinical and clinical studies have demonstrated the role of hOCT1, -2, and 
-3 in the disposition and efficacy of metformin, a hypoglycemic agent widely used for the treatment 
of type 2 diabetes mellitus [105, 164-166]. In humans, subjects carrying a mutated form of hOCT1 
with reduced function exhibited significantly altered pharmacokinetic properties of metformin that 
manifested as increased area under the plasma concentration-time curve, increased Cmax, and 
reduced oral volume of distribution, as well as reduced glucose-lowering effects, i.e., loss of 
efficacy [105, 166]. Given the predicted EMB portal vein concentration of 67 µM after oral dosing 
[141, 144, 149, 150], the rank order of DDI potencies for hOCT1 was enterocytes (0.6) = 
hepatocytes (0.6) ≥ proximal tubule cells (0.2); all the DDI indexes are above the 0.1 threshold 
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value (Figure 4.2 and Table 4.1). These results indicated that 38% of hOCT1 transport activity 
might be inhibited in enterocytes and hepatocytes during routine EMB therapy, suggesting a strong 
potential for EMB-metformin interactions in TB-diabetes patients. The IC50 for hOCT3 was higher 
(4.1 ± 1.6 mM) than those for hOCT1 and hOCT2 (Figure 4.4, bottom). However, given the 
expected high luminal GI tract concentration of EMB after oral dosing (~34 mM after a 1,750-mg 
dose [25 mg/kg in a 70-kg patient] diluted in 250 ml GI fluid), hOCT3 may represent an important 
pathway for GI absorption of EMB due to its apical membrane localization in enterocytes (Figure 
4.2). Furthermore, the estimated DDI index of 8.3 (Figure 4.4, bottom, and Table 4.1) is 83-fold 
higher than the DDI threshold value and is indicative of a marked potential for EMB to interfere 
(89% inhibition) with intestinal absorption of coadministered drugs that are hOCT3 substrates, 
including metformin. 
 As many anti-HIV agents are also hOCT substrates, the same DDI potential exists for 
polypharmacy in TB-HIV patients. Recently, expression of hOCT1 and hOCT2 mRNA was 
detected in CD4 cells isolated from patients with HIV [167]. Therefore, EMB present in the 
systemic circulation also might reduce accumulation of anti-HIV agents in CD4 target cells that 
serve as a viral reservoir, resulting in loss of antiviral efficacy via inhibition of hOCT1 and/or 
hOCT2 function. Similarly, systemic EMB might impact hOCT1-mediated (DDI index = 0.2; ~20% 
inhibition) and/or hOCT2-mediated (DDI index = 0.1; ~9% inhibition) renal secretion. 
 hOCTs are also involved in the pharmacological action of platinum antineoplastics (e.g., 
cisplatin and oxaliplatin), raising the possibility for significant DDIs during chemotherapy in TB 
patients [168-171]. Patients receiving cisplatin therapy frequently experience cumulative dose-
dependent nephrotoxicity involving the proximal tubule [172-174]. Moreover, treatment with 
inhibitors of hOCTs (e.g., tetraethylammonium and cimetidine) prevented accumulation of 
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cisplatin in renal proximal tubule cells, and subsequently, cisplatin was identified as a competitive 
inhibitor of rat Oct2 [168, 175-178]. Thus, coadministration of EMB and cisplatin or oxaliplatin 
might alter associated hepatic and renal accumulation and toxicity. 
 In summary, our findings demonstrate the inhibitory effect of EMB on hOCT1, hOCT2, 
and hOCT3, while its zwitterionic dicarboxylic metabolite EDA failed to produce significant 
inhibition of hOCT1, -2, and -3, hOAT1, or hOAT3. EMB concentrations in the GI tract and portal 
vein after oral administration indicate the potential for marked DDIs in vivo for hOCT1 expressed 
in hepatocytes, enterocytes, and potentially renal proximal tubule cells. Human OCT3 in 
enterocytes exhibited the highest DDI index, suggesting that EMB might significantly alter 
cationic drug/nutrient absorption. Renal hOCT2 has a slight possibility of EMB DDIs. Future 
investigations encompassing in vivo DDI studies between EMB and known substrates for hOCT1, 
hOCT2, and hOCT3 appear to be necessary in order to optimize clinical safety and efficacy in 
these complex patient populations. 
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CHAPTER 5    
 
 
INHIBITION OF HUMAN ORGANIC CATION TRANSPORTERS BY THE 
ALKALOIDS MATRINE AND OXYMATRINE 
 
 
Drawn from manuscript published in Fitoterapia. 2014, 92: 206–210. 
 
 
 
 
5.A INTRODUCTION   
Matrine and oxymatrine are the major quinolizidine alkaloids derived from several 
traditional Chinese medicinal herbs including Sophora alopecuroides (kudouzi), Sophora 
flavescens (kushen) and Sophora subprostrata [179-181]. In vivo, oxymatrine can be metabolized 
to form matrine in the GI tract and liver [180, 181]. Pharmacological studies have demonstrated 
that these compounds exhibit anti-arrhythmic, anti-viral, anti-immunodeficiency and anti-cancer 
activities [179, 180, 182]. The China State Food and Drug Administration database of drug 
manufacturing certificates currently lists 306 commercial matrine and oxymatrine preparations 
(http://www.sda.gov.cn/WS01/CL0001/). These pharmaceutical products, including granule, 
capsule, suppository and injectable dosage forms have been used in China for the treatment of viral 
hepatitis, cancer, and cardiac disease [183-186]. 
The analysis of their chemical structures indicated that matrine (pKa = 7.8) and oxymatrine 
(pKa = 6.0-6.7) might be positively charged at physiological pH [187, 188]. As a result, they have 
the potential to interact with organic cation transporters (OCTs) belonging to the Solute Carrier 22 
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(SLC22) family. OCTs mediate the absorption, distribution, and elimination of a broad array of 
positively charged endogenous and exogenous organic substances. Hundreds of clinically 
important therapeutics are known OCT substrates and/or inhibitors, including many antineoplastic 
(e.g., cisplatin, oxaliplatin and paclitaxel), antidiabetic (e.g. metformin) and antiviral (e.g., 
acyclovir and ganciclovir) agents [6, 163, 168, 189, 190]. OCTs are widely expressed in many 
organs including intestine, liver, kidney and brain [3, 6, 163]. Thus, OCT expression and function 
can be a major determinant of drug absorption across the GI tract, preferential tissue distribution, 
or active hepatic and renal drug excretion, which also leads to these transporters being frequent 
sites of drug-drug interaction (DDI). Indeed, numerous studies have demonstrated OCT-mediated 
DDIs between therapeutics [191]. Therefore, it is necessary to investigate potential OCT-mediated 
DDIs in order to establish informed safety and efficacy profiles for therapeutic products that 
contain OCT substrates and inhibitors. 
In the present study, inhibition of hOCT1-, hOCT2- and hOCT3-mediated 1-methyl-4-
phenylpyridinium (MPP+) transport by the alkaloids matrine and oxymatrine was explored. Potent 
inhibition was further quantified with kinetic studies to estimate the inhibitory constant (IC50). 
Inhibitory constant estimates were then used to aid evaluation of the potential for clinical DDIs on 
hOCTs.  
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5.B MATERIALS AND METHODS  
5.B.1 Chemicals  
Tritiated 1-methyl-4-phenylpyridinium ([3H]MPP+) was purchased from PerkinElmer Life 
and Analytical Science (Waltham, MA) and unlabeled MPP+ was obtained from Sigma-Aldrich 
(Saint Louis, MO). Matrine and oxymatrine were purchased from Fisher Scientific (Portland, OR). 
The chemical structures of matrine and oxymatrine are shown in Figure 5.1. Quinine 
monohydrochloride dihydrate was purchased from Acros Organics (Fair Lawn, NJ). 
 
 
 
Figure 5.1 Chemical structures of matrine and oxymatrine. 
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5.B.2 Tissue culture    
Derivation of the human embryonic kidney 293 (HEK) cells stably transfected with hOCT1 
(HEK-hOCT1), hOCT2 (HEK-hOCT2), hOCT3 (HEK-hOCT3), or the corresponding empty 
vector (background control), has been described previously [14, 107, 121, 148]. The HEK cell 
lines were maintained at 37C with 5% CO2 in DMEM high glucose media containing 10% serum, 
1% Pen/Strep and 600 µg/mL G418.   
5.B.3 Cell accumulation assay     
The procedure for cell accumulation assay was described previously with minor 
modification [123]. Briefly, cells were seeded into 24-well tissue culture plates at a density of 
2×105 cells/well in antibiotics-free medium. After 2 days, the cells were initially equilibrated with 
transport buffer for 10 min (500 µL of Hanks’ balanced salt solution containing 10 mM HEPES, 
pH 7.4). The cells were then treated with 500 µL of fresh transport buffer containing 1 µM 
unlabeled substrate spiked with [3H]MPP+ (0.25 µCi/mL) in the presence or absence of test 
compounds. At the end of the incubation, the cells were quickly rinsed three times with ice-cold 
transport buffer and lysed with 1M NaOH. The radioactivity of cell lysate was quantified by liquid 
scintillation counting, and the uptake profile was normalized by the total protein content 
determined by the Bradford method. The cellular uptake of substrates was shown as picomoles of 
substrate per milligram total protein. All uptake data were corrected for background accumulation 
in corresponding empty vector transfected control cells. Kinetic calculations were performed using 
GraphPad Prism Software version 5.0 (GraphPad Software Inc., San Diego, CA). The half 
maximal inhibitory concentration (IC50) was calculated using nonlinear regression with the 
appropriate model. All experiments were repeated at least three times with triplicate wells for each 
data point. 
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5.B.4 Statistical analysis    
Data in figures and reported raw uptake scores are expressed as mean ± SD, while IC50 
estimates are mean ± SEM. Statistical differences were analyzed using one-way ANOVA followed 
by Dunnett’s post-hoc t-test (α=0.05).  
5.C RESULTS  
5.C.1 Inhibitory effects of matrine and oxymatrine on hOCT1-mediated MPP+ uptake  
Stably transfected hOCT1-expressing (HEK-hOCT1) cells showed marked accumulation 
of MPP+ (~42 fold) compared to empty vector transfected background control cells (300 ± 53 vs. 
7.1 ± 0.4 pmol/mg protein/15 min, respectively). The known OCT inhibitor, quinine, showed 
virtually complete inhibition of hOCT1-mediated MPP+ uptake at 200 µM (>90% inhibition; 
Figure 5.2A). Matrine and oxymatrine produced 26% and 35% inhibition of hOCT1 transport 
activity at 100 µM (Figure 5.2A). Subsequently, a dose-response study (1 to 5000 µM) was 
performed on hOCT1 to derive the IC50 value for oxymatrine, which showed a much higher plasma 
level in patients (68 µM) compared to matrine (8.1 µM) [192, 193]. The IC50 value was estimated 
as 513 ± 132 µM (Figure 5.2B). 
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Figure 5.2 Inhibition of hOCT1 by matrine and oxymatrine.  
A: Inhibition of hOCT1-mediated MPP+ (1 µM) uptake by matrine (100 µM), oxymatrine (100 
µM) and quinine (200 µM) was assessed at 15 min. Values are mean ± SD of triplicate samples. 
*** denotes p < 0.001 as determined by one-way ANOVA followed by Dunnett’s t-test. B: Dose-
response curve for oxymatrine on hOCT1. One minute uptake of MPP+ (1 µM) was measured in 
HEK-hOCT1 cells in the presence of increasing concentrations of oxymatrine (1×10-6 to 5×10-3 
M). The IC50 was estimated using non-linear regression and the “log(inhibitor) vs. response” model 
(GraphPad Prism). All data were corrected for non-specific background measured in control cells. 
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5.C.2 Inhibitory effects of matrine and oxymatrine on hOCT2-mediated MPP+ uptake  
Significantly increased cellular accumulation of MPP+ was observed in stably transfected 
hOCT2-expressing cells (~21 fold) as compared to background control (empty vector) cells (150 
± 17 vs. 7.1 ± 0.4 pmol/mg protein/15 min, respectively). Similarly, quinine completely blocked 
(>99%) hOCT2-mediated MPP+ uptake at 200 µM (Figure 5.3). However, neither of these 
compounds showed significant inhibition at 100 µM. As a result, further kinetic analysis was not 
performed.  
5.C.3 Inhibitory effects of matrine and oxymatrine on hOCT3-mediated MPP+ uptake   
Like hOCT1 and hOCT2, stably transfected hOCT3-expressing cells exhibited greater 
MPP+ uptake (189 ± 27 pmol/mg protein/15 min) than control cells (7.1 ± 0.4 pmol/mg protein/15 
min), and this active transport was completely blocked (99%) by quinine at 200 µM (Figure 5.4). 
Since hOCT3 expressed on the apical side of enterocytes would likely be exposed to higher 
concentrations of these compounds after oral administration, the inhibitory effects on hOCT3 were 
investigated at increasing concentration levels. While matrine and oxymatrine each failed to 
produce significant inhibition on hOCT3 transport activity at 100 µM, marked inhibition was 
observed at elevated concentrations (Figure 5.4). Oxymatrine showed ~26% and ~42% inhibition 
at 1 and 3 mM, respectively, suggesting an IC50 ≥ 3 mM (Figure 5.4A). Similarly, matrine showed 
~34% and ~88% inhibition on hOCT3 at 1 and 6 mM, respectively, suggesting 1 mM < IC50 < 6 
mM (Figure 5.4B).     
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Figure 5.3 Inhibition of hOCT2 by matrine and oxymatrine.  
Inhibition of hOCT2-mediated MPP+ (1 µM) uptake by matrine (100 µM), oxymatrine (100 µM) 
and quinine (200 µM) was assessed at 15 min. Values are mean ± SD of triplicate samples. Data 
were corrected for non-specific background measured in control cells. 
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Figure 5.4 Inhibition of hOCT3 by matrine and oxymatrine.  
A: Inhibition of hOCT3-mediated MPP+ (1 µM) uptake by oxymatrine (100 µM, 1 mM and 3 mM) 
and quinine (200 µM) was assessed at 15 min. B: Inhibition of hOCT3-mediated MPP+ (1 µM) 
uptake by matrine (100 µM, 1 mM and 6 mM) and quinine (200 µM) was assessed at 15 min. Data 
were corrected for non-specific background measured in control cells. Values are mean ± SD of 
triplicate samples. *** denotes p < 0.001 as determined by one-way ANOVA followed by 
Dunnett’s t-test. 
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5.D DISCUSSION   
Herb-drug interactions, which can manifest as impaired drug efficacy and/or enhanced 
toxicity when patients use natural products and prescribed drugs in combination, have been 
documented in both pre-clinical and clinical investigations [194]. Increasingly, studies have 
demonstrated transporter proteins as being the site of drug-drug and botanical-drug interactions 
[123, 124, 195]. In China, the plant alkaloids matrine and oxymatrine are widely used in clinical 
therapy due to their broad applications, including the treatment of cancer and viral hepatitis. 
Therefore, the information on potential DDIs is even more critical for those who suffer from 
chronic diseases (e.g., HIV and hepatitis C viral infections, cancer) and depend on long-term or 
even life-time treatment. As OCTs interact with many anti-viral and anti-neoplastic drugs, there is 
a need to better understand the interaction of OCTs with the botanical alkaloids matrine and 
oxymatrine. 
hOCT1 plays an important role in hepatic and renal secretion and uptake, and inhibition of 
hOCT1 would potentially impair hepatic metabolism, biliary excretion and renal elimination. A 
number of antiretroviral drugs, including lamivudine, zalcitabine, pentamidine, and trimethoprim, 
have been identified as substrates of hOCT1, and oxymatrine and matrine are commonly combined 
with these drugs during antiviral therapy [163, 196]. In clinical practice, both injectable and oral 
dosage forms are used. The maximum plasma concentration (Cmax) was reported as 68 µM after 
i.v. infusion of 600 mg of oxymatrine [193]. Accordingly, the ratio of Cmax over IC50 (as an 
indicator of DDI potential) of oxymatrine on hOCT1 was 0.13. While the fraction of plasma 
protein binding in humans for oxymatrine is unknown, it was reported to be 19% in rats (i.e., 81% 
exists as the free form) [197]. Assuming similar binding for humans, the DDI index, calculated as 
unbound Cmax/IC50, still would be 0.1. Currently, the FDA Guidance for Drug Interaction Studies 
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suggests that a DDI index > 0.1 indicates that a DDI may occur in vivo [129]. While hOCT2 is 
another important transporter involved in renal elimination, the relatively low affinity for matrine 
and oxymatrine makes it unlikely to be a site for relevant DDIs involving these compounds. 
Studies with knockout mice and human tissue have confirmed expression and function of 
OCT3 in cardiac tissues, although the specific cell type(s) and membrane targeting are still unclear 
[198, 199]. Regardless, given the plasma levels associated with the clinical use of matrine and 
oxymatrine, significant DDIs with hOCT3 expressed in the heart are not indicated. In enterocytes, 
hOCT3 is expressed in the apical membrane and functions as an uptake transporter in the intestinal 
absorption of cationic drugs. Many in vivo studies have demonstrated that inhibition of apical 
enterocyte uptake transporters resulted in reduced bioavailability of substances handled by these 
transporters [200]. Both matrine and oxymatrine are water soluble (~100 g/L), therefore, as 
suggested by the FDA Guidance for Industry regarding the design and analysis of drug interaction 
studies, the concentration of matrine and oxymatrine in the GI tract after oral administration can 
be estimated by the ratio of the dose over 250 mL, assuming that patients take their medications 
with 250 mL of water [129]. According to the oral doses of matrine (400 mg) and oxymatrine (300 
mg) reported in clinical studies, the maximum concentration of each could reach 6.5 and 4.5 mM, 
respectively [192, 201]. Our results showed that matrine and oxymatrine produced 42% and 88% 
inhibition on hOCT3 transport activity at 3 and 6 mM, respectively, indicating that concentrations 
of matrine and oxymatrine in the GI tract after oral clinical dosing could be high enough to block 
hOCT3-mediated intestinal absorption of cationic drugs. Therefore, in vivo studies should be 
conducted to investigate the potential influence of matrine and oxymatrine on the intestinal 
absorption of co-administered therapeutics that are hOCT3 substrates. 
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In summary, our findings demonstrated the inhibitory effects of matrine and oxymatrine 
on hOCTs. Clinically, oxymatrine could interfere with hOCT1-mediated hepatic uptake and renal 
elimination, and hOCT3-mediated intestinal absorption processes. Matrine only has the potential 
to block hOCT3 expressed in enterocytes. In vivo DDI studies between oxymatrine or matrine and 
known substrates for hOCT1 and hOCT3 appear necessary in order to establish informed safety 
guidelines for the development, approval and use of products containing these active alkaloids.  
  
 
 
77 
 
 
CHAPTER 6    
 
 
INHIBITION OF HUMAN ORGANIC CATION TRANSPORTERS BY SYNTHETIC 
CATHINONE ANALOGS (“BATH SALTS”) 
 
 
 
 
6.A INTRODUCTION   
 The abuse of designer drugs ‘bath salts’ has been an escalating public health crisis in 
Europe and the United States (US). In 2011, the American Association of Poison Control Center 
received 6137 calls about exposures to ‘bath salts’, representing ~20-fold increase from the cases 
in 2010 (306 calls) [202]. In the United Kingdom, the reports of seizures related to ‘bath salt’ use 
increased from less than 10 cases in 2009 to 650 cases in 2010 [203]. The psychoactive 
components of ‘bath salts’, including methcathinone, 4-methylmethcathinone (mephedrone), 3,4-
methylenedioxymethcathinone (methylone) and 3,4- methylenedioxypyrovalerone (MDPV), are 
mainly synthetic derivatives of cathinone, a naturally occurring β-ketone analog of amphetamine 
found in the plant khat (Catha edulis). These synthetic cathinones, like other psychostimulants 
(e.g., amphetamine, methamphetamine, and cocaine), profoundly interact with monoaminergic 
systems in the central nervous system (CNS). Pharmacological studies have demonstrated that 
synthetic cathinones increases brain interstitial fluid concentration of some neurotransmitters (e.g. 
dopamine (DA) and serotonin (5-HT)), via increasing the release and/or inhibiting the uptake of 
these substances in the CNS, producing various psychoactive effects [204-208]. Evidence of this 
has been shown in vivo with microdialysis studies where mephedrone and methylone rapidly 
 
 
78 
 
increased the extracellular levels of DA and serotonin 5-HT in rat brain after subcutaneous (s.c.) 
or intravenous (i.v.) administration [204-206]. In addition, long-term serotonergic deficit was 
observed after repeated mephedrone injection [208]. To better understand the mechanism of action 
of synthetic cathinones, the interaction of bath salts with monoamine reuptake transporters in the 
CNS has received considerable interest. Currently, two distinguishable mechanisms of aminergic 
neurotransmitter clearance in the synapse have been recognized: uptake-1 (high-affinity, low 
capacity reuptake transporters) and uptake-2 (low-affinity, high capacity reuptake transporters) 
[91, 92]. Up to now, extensive studies have demonstrated the interaction between synthetic 
cathinones and uptake-1 transporters, such as dopamine transporter (DAT; SLC6A3), serotonin 
transporter (SERT; SLC6A4) and norepinephrine transporter (NET; SLC6A2) [206-208]. 
methcathinone, mephedrone, and methylone have been shown to be non-selective substrates of 
DAT, SERT and NET, stimulating the transporter-mediated release of monoamine 
neurotransmitters via reversal of normal transporter flux, while MDPV was demonstrated to be an 
inhibitor for DAT and NET without any measureable substrate activity [206, 208, 209].  The 
potential interaction of synthetic cathinones with uptake-2 transporters, including the organic 
cation transporters (OCTs; SLC22 family), has not been investigated.  
 OCTs are membrane proteins that interact with a broad variety of cationic and zwitterionic 
organic molecules [3]. Three OCT subtypes, OCT1 (SLC22A1), OCT2 (SLC22A2) and OCT3 
(SLC22A3) are widely expressed in many barrier organs (e.g. liver, kidney and choroid plexus) 
and in vivo mediate the absorption, distribution, and elimination of numerous endogenous and 
exogenous compounds [3]. Recently, there has been increasing evidence indicating that 
OCT2/Oct2 and OCT3/Oct3 are widely expressed in different brain regions and actively involved 
in the CNS aminergic neurotransmitter homeostasis. Firstly, when examined in vitro human (h) 
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OCTs and murine (m) Octs actively transport neurotransmitters such as 5-HT, NE and DA, albeit 
it with lower affinity (Km values in higher micromolar range) compared to uptake-1 transporters 
(Km values in nanomolar to lower micromolar range) [3, 75, 210-212]. Moreover, in vivo intra-
hypothalamic perfusion of the OCT inhibitor, decynium-22 (D-22), increased extracellular 5-HT 
concentrations (2-6.5 fold) in a dose-dependent manner [94]. This increase was comparable to that 
observed after fluoxetine (an selective serotonin reuptake inhibitor) was administered via the same 
route [95]. The expression and function of mOct3 in the CNS were significantly increased in SERT 
knockout mice, indicating that mOct3 may serve as a compensation modulator of neurotransmitters 
in brain when SERT function is compromised [100, 101]. Furthermore, mOct2 knockout mice 
displayed reduced tissue concentration of NE and 5-HT in several brain regions (e.g., cortex, 
hippocampus, and striatum) as compared to wild-type mice [77]. Together, converging lines of 
evidence lead to the hypothesis that OCTs function as important components of the uptake-2 
pathway, and thus may represent an equally important target for psychostimulants such as 
synthetic cathinone as the uptake-1 pathway.  
 As low molecular weight compound that are protonated in the physiological environment 
(pH=7.4), synthetic cathinones have the potential to be substrates and/or inhibitors of OCTs. The 
aim of the present study was to explore the inhibitory effects of mephedrone, methylone and 
MDPV on hOCT1-, hOCT2-, and hOCT3-mediated transporter. In addition, since 
S(-)methcathinone and R(+)methcathinone showed different psychoactive activities [213], the 
inhibitory effects of each methcathinone enantiomer on hOCT1, hOCT2 and hOCT3 were also 
investigated. Potent inhibition was further characterized by kinetic investigations to estimate IC50 
values, which were used to quantitatively evaluate the potential of drug-neurotransmitter 
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interaction or drug-drug interactions (DDIs) in the CNS and peripheral organs after bath salts 
consumption.  
6.B METHODS 
6.B.1 Chemicals   
 Tritiated 1-methyl-4-phenylpyridinium ([3H]MPP+) was obtained from PerkinElmer Life 
and Analytical Science (Waltham, MA) and unlabeled MPP+ was purchased from Sigma-Aldrich 
(Saint Louis, MO). Quinine monohydrochloride dihydrate was obtained from Acros Organics (Fair 
Lawn, NJ). S(-)methcathinone, R(+)methcathinone, mephedrone, methylone and MDPV were 
synthesized as previously described [213-216]. The chemical structures of S(-)methcathinone, 
R(+)methcathinone, mephedrone, methylone and MDPV are shown in Figure 6.1.  
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Figure 6.1 Chemical structures of synthetic cathinones.  
 
 
 
 
 
82 
 
6.B.2 Tissue culture   
 Derivation of the human embryonic kidney 293 (HEK) cells stably transfected with hOCT1 
(HEK-hOCT1), hOCT2 (HEK-hOCT2), hOCT3 (HEK-hOCT3), as well as the corresponding 
empty vector transfected cells (background control), has been described previously [14, 148]. The 
HEK cell lines were maintained in DMEM high glucose media containing 10% of fetal bovine 
serum and 1% Pen/Strep at 37°C in an atmosphere of 5% CO2. G418 (600 μg/mL) was added to 
the media for the selection of transfected cells.      
6.B.3 Cell accumulation assays   
 The procedure for cell accumulation assay has been described previously with minor 
modification [123, 124]. Briefly, 2×105 cells/well were seeded in 24-well tissue culture plates in 
the absence of antibiotics and grown until confluence. Before the cell transport experiment, cells 
were preincubated in 500 μL transport buffer (Hanks’ balanced salt solution containing 10 mM 
HEPEs, pH 7.4) for 10 min. After equilibration, the transport buffer was replaced with 500 μL of 
fresh transport buffer containing unlabeled MPP+ (1 μM) spiked with [3H]MPP+ (0.25 μCi/mL) in 
the presence or absence of test compounds. At the end of the incubation, the cells were quickly 
rinsed three times with ice-cold transport buffer and lysed with 1 M NaOH. The intracellular 
radioactivity of cell lysate was counted by liquid scintillation and reported as pmol of substrate per 
milligram total protein. The total protein content of each well was determined by the Bradford 
method. All uptake data were corrected for background accumulation in corresponding empty 
vector transfected cells. Kinetic calculations were performed using GraphPad Prism Software 
version 5.0 (GraphPad Software Inc., San Diego, CA). The half maximal inhibitory concentration 
(IC50) was calculated using nonlinear regression with the appropriate model. All experiments were 
repeated at least three times with triplicate wells for each data point. 
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6.B.4 Statistics   
 Data in figures and reported raw uptake scores are expressed as mean ± SD, while IC50 
estimates are mean ± SEM. Statistical differences were analyzed using one-way ANOVA followed 
by Dunnett’s post-hoc t-test (α=0.05).   
6.C Results  
6.C.1 Inhibitory effects of synthetic cathinones on hOCT1-mediated MPP+ uptake   
 Stably transfected HEK-hOCT1 cells demonstrated marked accumulation of MPP+ (~21 
fold) compared to empty vector control cells (43.8 ± 1.0 vs. 2.13 ± 0.2 pmol/mg protein/10 min, 
respectively; data not shown). The known hOCT1 inhibitor, quinine (200 µM), produce virtually 
complete inhibition of hOCT1-mediated MPP+ uptake (>90% inhibition; Figure 6.2). The cell 
accumulation assay demonstrated that mephedrone, methylone, MDPV, as well as both optical 
isomers of methcathinone, significantly inhibited hOCT1-mediated MPP+ transport (>50%) at 100 
µM (Figure 6.2). Dose-response studies were performed to estimate the IC50 values of synthetic 
cathinones for hOCT1. Decreased transport activity of hOCT1 was observed in the presence of 
increasing concentrations of synthetic cathinones (0.01-5000 µM). The IC50 values of synthetic 
cathinones for hOCT1 ranged from 6.5-31.5 µM (Figure 6.3 and Table 6.1). Among five synthetic 
cathinones, MDPV (IC50 = 6.5 ± 1.3 μM) exhibited the lowest IC50 for hOCT1, whereas 
S(-)methcathinone (IC50 = 31.5 ± 8.9 μM) showed the highest IC50 value for hOCT1. 
R(+)methcathinone exhibited ~4 fold stronger affinity with hOCT1 than S(-)methcathinone (IC50 
= 8.4±1.9 μM vs. 31.5 ± 8.9 μM).   
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Figure 6.2 Inhibition of hOCT1-, hOCT2 and hOCT3-mediated uptake by synthetic 
cathinones.  
Cellular uptake of [3H]MPP+ (1 µM, 10 min) was measured in HEK-hOCT1, HEK-hOCT2 and 
HEK-hOCT3 expressing cells in the absence and presence of synthetic cathinones (100 µM) or 
quinine (200 µM). All data were corrected for background MPP+ accumulation measured in 
corresponding empty vector transfected cells. Values are mean ± S.D. of triplicate values. 
Significant inhibition denoted by ***p < 0.001 as determined by one-way ANOVA followed by 
Dunnett’s t-test.   
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Figure 6.3 Dose–response curves for synthetic cathinones with respect to hOCT1.  
One minute uptake of [3H]MPP+ (1 µM) in HEK-hOCT1 cells was measured in the presence of 
increasing concentrations (10-7 to 10-2.3 M) of test compounds. Data were corrected for non-specific 
background measured in the corresponding empty vector transfected background control cell. IC50 
values were determined with nonlinear regression and the “log(inhibitor) vs. response” model. 
Experiments were repeated three times in triplicate with the mean IC50 ± S.E.M. reported in Table 
6.1. Graphs shown are from representative experiments with values plotted as mean ± S.D. (n = 
3).    
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6.C.2 Inhibitory effects of synthetic cathinones on hOCT2-mediated MPP+ uptake   
 Markedly increased cellular accumulation of MPP+ was observed in stably transfected 
HEK-hOCT2 cells (~34 fold) as compared to background control (empty vector) cells (56.7 ± 2.1 
vs. 1.5 ± 0.2 pmol/mg protein/10 min, respectively; data not shown). Similarly, quinine completely 
blocked (>99%) hOCT2-mediated MPP+ uptake at 200 μM (Figure 6.2). The tested synthetic 
cathinones (100 μM) produced approximately 80% inhibition on hOCT2-mediated MPP+ transport 
(Figure 6.2). Kinetic studies, applying increasing concentrations of test compounds (0.01-5000 
µM), were performed to determine the IC50 values on hOCT2. S(-)methcathinone demonstrated 
the lowest IC50 value (IC50 = 11.9 ± 2.9 μM) for hOCT2, and R(+)methcathinone, mephedrone, 
methylone, and MDPV showed similar IC50 values on hOCT2, ranging from 16.7 to 20.9 μM 
(Figure 6.4 and Table 6.1). 
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Figure 6.4 Dose–response curves for synthetic cathinones with respect to hOCT2.  
 
One minute uptake of [3H]MPP+ (1 µM) in HEK-hOCT2 cells was measured in the presence of 
increasing concentrations (10-7 to 10-3 M) of test compounds. Data were corrected for non-specific 
background measured in the corresponding empty vector transfected background control cell. IC50 
values were determined with nonlinear regression and the “log(inhibitor) vs. response” model. 
Experiments were repeated three times in triplicate with the mean IC50 ± S.E.M. reported in Table 
6.1. Graphs shown are from representative experiments with values plotted as mean ± S.D. (n = 
3).   
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6.C.3 Inhibitory effects of synthetic cathinones on hOCT3-mediated MPP+ uptake   
 Cellular accumulation of MPP+ was significantly increased in stably transfected HEK-
hOCT3 cells (~21 fold) as compared to background control (empty vector) cells (26.9 ± 2.9 vs. 
1.3 ± 0.2 pmol/mg protein/10 min, respectively; data not shown). Inhibition by quinine (200 µM) 
was complete (>99%; Figure 6.2). R(+)methcathinone, mephedrone and MDPV showed marked 
inhibitory effects on hOCT3 transport activity at 100 μM, while methylone and S(-)methcathinone 
failed to produce significant inhibition. Accordingly, further kinetic studies were performed to 
derive the IC50 values for R(+)methcathinone, mephedrone and MDPV (Figure 6.5 and Table 6.1). 
Estimated IC50 values of R(+)methcathinone, mephedrone, and MDPV were 174.0 ± 16.7 µM, 
334.7 ± 86.7 µM, 130.5 ± 18.0 µM , respectively.  
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Figure 6.5 Dose–response curves for synthetic cathinones with respect to hOCT3.  
 
One minute uptake of [3H]MPP+ (1 µM) in HEK-hOCT3 cells was measured in the presence of 
increasing concentrations (10-6 to 10-2.3 M) of test compounds. Data were corrected for non-specific 
background measured in the corresponding empty vector transfected background control cell. IC50 
values were determined with nonlinear regression and the “log(inhibitor) vs. response” model. 
Experiments were repeated three times in triplicate with the mean IC50 ± S.E.M. reported in Table 
6.1. Graphs shown are from representative experiments with values plotted as mean ± S.D. (n = 
3).   
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Table 6.1 Estimated IC50 (µM) and inhibitory potency of synthetic cathinone for hOCT1, hOCT2 and hOCT3.  
Compounds 
IC50 (μM) 
fua 
(%) 
Cb 
(μM) 
C brainc 
(μM) 
Brain  
(% inhibition) 
Heart 
 (% inhibition) 
Liver and kidney 
(DDI index)d 
hOCT1 hOCT2 hOCT3 hOCT2 hOCT3 hOCT3 hOCT1 hOCT2 hOCT3 
Mephedrone 8.6 ± 2.2 18.8 ± 2.7 334.7 ± 86.7 
78.4
% 
0.7-
124.2f 
0.6-
99.4 
84% 23% 35% 20.6 9.4 0.5 
Methylone 11.5 ± 1.1 20.9 ± 3.4 >> 100 70% 0.3-5.4f 0.2-4.3 17% NDh ND 0.6 0.3 < 0.1 
MDPV 6.5 ± 1.3 16.7 ± 1.2 130.5 ± 18.0 ?e 2.3f 0.1-3.3 17% 2% < 3% 0.5 0.2 < 0.1 
S(-)methcathinone 31.5 ± 8.9 11.9 ± 2.9 >> 100 ? 3.1g 4.5 27% ND ND < 0.1 0.2 < 0.1 
R(+)methcathinone 8.4 ± 1.9 20.4 ± 4.5 174.0 ± 16.7 ? 3.1g 4.5 18% 3% < 2% 0.3 0.1 < 0.1 
Values are reported as mean ± S.E.M.  
a fu, fraction unbound in plasma. 
b Clinical drug concentrations in blood or serum were reported from [217-223].  
c Brain concentration of mephedrone as reported in [217, 221]. Brain concentrations of methylone, MDPV, S(-)methcathinone and 
R(+)methcathinone were estimated based on brain to blood concentration ratio.  
d Drug-drug Interaction index is defined as the unbound concentration of drug divided by the drug IC50 for the transporter of interest. 
A DDI index value > 0.1 is thought to indicate the potential for clinically relevant DDIs 
e ?, unknown and assume the plasma protein binding is 70%.  
f blood concentration. 
g serum concentration.  
h ND, not determined.   
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6.D Discussion   
The abuse of synthetic cathinones has exhibited a dramatic increase in the US and Europe 
over the last decade, which brings serious public health concerns. However, there is limited 
understanding about the mechanism of action of these notorious compounds. Even though 
numerous studies have demonstrated that synthetic cathinones regulate extracellular concentration 
of DA and 5-HT via uptake-1 transporters, DAT, SERT, and NET, exerting psychoactive effects 
[206-208], the influence from other pathways, including those that involve uptake-2 transporters, 
might be also important. Given the increasing evidence showing the expression of OCTs in 
astrocytes and cerebellum granule neurons in cerebellum, subfornical organ, dorsal raphe, 
hypothalamic nuclei, cortex and hippocampus regions in brain [77, 78, 82, 224-226], and their 
active role in the regulation of neurotransmitter homeostasis, it is necessary to investigate the 
interaction of synthetic cathinones with hOCTs. 
In the present study, all tested synthetic cathinones were found to be potent inhibitors for 
hOCTs. Specifically, three commonly identified synthetic cathinones, mephedrone, methylone, 
and MDPV, demonstrated stronger inhibitory effects on hOCT1 and hOCT2 as compared to 
hOCT3. In addition, methcathinone isomers exerted unique patterns of interaction with hOCTs. 
The IC50 value of S(-)methcathinone for hOCT1 is ~4 fold higher (poorer affinity) than 
R(+)methcathinone, whereas the IC50 value of R(+)methcathinone for hOCT2 is ~2 fold higher 
(poorer affinity) than S(-)methcathinone. Similar to hOCT2, R(+)methcathinone, rather than 
S(-)methcathinone, showed significant inhibitory effects on hOCT3, albeit with the poorest affinity 
(~174 µM).  
In order to estimate the inhibitory effects of synthetic cathinones for organic cation 
transporters in the CNS, it is important to know the brain concentration of these compounds [227]. 
 
 
92 
 
As the brain concentration of MDPV was reported as 0.1-3.3 µM in postmortem cases [217, 221], 
the maximum possible inhibition on hOCT2 in the brain would be 17%, while such inhibitory 
effects on hOCT3 is low (<3%). In addition, the blood concentration of mephedrone and 
methylone were 0.7-124.2 µM [218, 219, 222] and 0.3-5.4 µM [217, 218], respectively. Even 
though the brain concentration of the two compounds is not available, as brain to blood 
concentration ratio of MDPV was 0.8 [228], we assumed that these cathinone derivatives obtained 
similar partitioning between blood and brain. As the consequence, mephedrone was predicted to 
produce maximally 84% and 23% inhibition on hOCT2 and hOCT3, respectively, while methylone 
is less likely to cause significant inhibition of hOCT2 and hOCT3 (~17% and less than 4% on 
hOCT2 and hOCT3, respectively). Therefore, inhibition of hOCT2 and hOCT3 in the CNS by 
synthetic cathinones could very well result in increase in extracellular monoamine levels and 
possibly cause psychoactive effects [77, 95, 208].  
In mice, S(-)methcathinone was about 3-5 times more potent than R(+)methcathinone 
locomotor activity tests and training effects [213, 229]. The discriminative central stimulant effects 
of these methcathinone optical isomers may be, at least partially, due to their differing affinities 
for OCTs/Octs. Perhaps indicating a greater role for OCTs as this transporter exhibited stronger 
interactions than OCT1 or 3 with S(-)methcathinone. The fact that hOCT2 preferentially interacts 
with S(-)methcathinone might contribute to differing pharmacological effects of these two 
compounds. 
In addition to the psychoactive effect, cardiovascular complications (e.g. sinus tachycardia, 
palpitations and hypertension) are very common among ‘bath salts’ abusers [230, 231]. The 
cardiovascular syndromes are often associated with reduced cardiac extraction of NE from the 
plasma to heart [232-234], which might at least partially, be attributed to OCTs which are also 
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expressed in capillary and vascular endothelial cells of the heart [15, 199]. Indeed, O-methyl-
isoprenaline, the selective hOCT3 inhibitor, abolished concentration difference of NE between the 
interstitial space and vascular bed in rat heart [235, 236]. In the present study, the IC50 values of 
mephedrone, MDPV and R(+)methcathinone on hOCT3 were 334.7 ± 86.7 µM, 130.5 ± 18.0 µM 
and 174.0 ± 16.7 µM, respectively. Based on the reported clinical blood concentration of 
mephedrone (124.2 µM) [218, 219, 222], the plasma protein binding (21.6%) [237] and assuming 
55% plasma to blood ratio [237], mephedrone is predicted to inhibit 35% transport activity for 
hOCT3. 
OCTs also play an important role in biliary and renal elimination. hOCT1 and hOCT3 are 
expressed in the sinusoidal membrane of hepatocytes and represent the first step in the hepatic 
uptake of many substances, while hOCT2 and hOCT3 are expressed on the basolateral side of 
proximal tubular cells in the kidney [3]. Clinical studies have demonstrated that impairment of 
transport function of OCTs might alter the pharmacokinetic properties of other drugs that are 
substrates for OCTs such as metformin and morphine [105, 166, 238]. The Food and Drug 
Administration recommends using DDI index (ratio of unbound Cmax to Ki or IC50) to estimate the 
drug-drug interaction potency [129], and DDI index > 0.1 indicates the significant DDI potential 
in vivo. As shown in Table 6.1, these compounds demonstrated DDI index greater than 0.1 at least 
for one hOCT subtype, and mephedrone showed much higher DDI index ( >9 ) on hOCT1 and 
hOCT2. These results suggested that synthetic cathinones have a great potential to inhibit hOCTs, 
rendering reduced hOCT1- and hOCT2- mediated renal tubular secretion and biliary elimination. 
Interaction of hOCT3 was not predicted to result in any potentially significant DDIs. Forensic 
studies have reported that synthetic cathinone abusers are also likely to simultaneously take heroin, 
cocaine and morphine [217]. Morphine is an opioid analgesic as well as a major metabolite of 
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heroin and cocaine [238]. A previous study has demonstrated that morphine was a substrate of 
hOCT1 and the plasma concentrations of morphine in healthy volunteers were significantly 
affected by hOCT1 polymorphisms [238]. Therefore, combination use of synthetic cathinones and 
morphine, heroin or cocaine may increase the plasma concentration of morphine to the lethal range. 
Indeed, toxicological studies demonstrated that toxicity and rate of fatality were significantly 
amplified when ‘bath salts’ were combined with abused drugs [239-241].    
In summary, our findings demonstrated that mephedrone, methylone, MDPV, 
S(-)methcathinone and R(+)methcathinone are inhibitors for hOCT1, hOCT2 and hOCT3. These 
finding suggest that the psychoactive effects of synthetic cathinones might be due to their 
inhibitory effects on hOCT2 and hOCT3 that modulate neurotransmitters reuptake in the CNS. In 
addition, the inhibition of hOCT3 by synthetic cathinone, interferes with NE reuptake in cardiac 
endothelial cells and could potentially cause cardiovascular complications. Finally, synthetic 
cathinones showed significant DDI potential on hOCT1 and hOCT2, which might explain the 
enhanced toxicities when bath salts were combined with other abused drugs such as codeine, 
morphine and heroin. The role of OCTs in the biological effects of synthetic cathinones as well as 
elucidating their in vivo DDI potential would be important future studies to conduct to provide 
increased insight in completing the full mechanistic picture.   
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CHAPTER 7  
 
 
THERAPEUTIC POTENTIAL OF NOVEL ORGANIC CATION TRANSPORTER 
(OCT; SLC22 FAMILY) INHIBITORS IN DEPRESSION  
 
 
 
 
7.A INTRODUCTION  
Depressive disorder is among the most serious and burdensome psychiatric illnesses in the 
world. Currently, approximately 17% of the US population suffers from depression and it 
generates about 60 billion dollars in medical costs annually in the US [242]. Although numerous 
classes of psychoactive drugs are used in the treatment of depression, undesirable side effects and 
delayed onset of action are often observed in clinical applications [243, 244].  In addition, current 
antidepressant treatment fails to produce beneficial effects in nearly 50% of the patient population 
[243, 245-247].   
Depression is often associated with a reduction of monoaminergic neurotransmitters such 
as serotonin (5-HT) and/or norepinephrine (NE) in the synaptic clefts [92, 246]. Currently, most 
antidepressants are thought to exert their pharmacological effects via blocking uptake-1, the high 
affinity, low capacity reuptake system, i.e., serotonin transporter (SERT) and norepinephrine 
transporter (NET). For example, the most prevalent antidepressants on the market, selective 
serotonin reuptake inhibitors (SSRIs, e.g., fluoxetine and sertraline) and selective serotonin and 
norepinephrine reuptake inhibitors (SNRIs, e.g, venlafaxine and duloxetine), target SERT and/or 
NET. However, there is also a second low-affinity, high capacity clearance pathway for biogenic 
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amines, uptake-2. Increasing evidence has indicated that organic cation transporter 2 (OCT2) and 
3 (OCT3), which are widely expressed in the CNS, interact with dopamine (DA), 5-HT and NE 
and likely represent an important component of the uptake-2 pathway, playing a role in the 
regulation of CNS neurotransmitter homeostasis [92]. For example, intra-hypothalamic perfusion 
of the OCT inhibitor, decynium-22, dose-dependently increased extracellular 5-HT concentrations 
by approximately 2-6.5 fold [94], which was comparable to the action of fluoxetine (~4 fold) via 
the same route of administration [95]. Furthermore, the expression and function of murine (m)Oct3 
in the CNS was significantly increased in SERT knockout mice, indicating that mOct3 may be an 
important modulator of neurotransmitters in brain when SERT function is compromised [100, 
101]. Therefore, OCTs may represent unrecognized targets of known antidepressants and may 
impact their pharmacological action.  
Recently, a series of quinazolines and guanidines were developed as potential novel 
therapeutic agents for depression in the laboratory of Dr. Dukat [248, 249]. The experimentally 
determined logP value for KEO-099 was 1.86, suggesting a favorable ability to penetrate the 
blood-brain barrier [248, 249]. In the murine tail suspension test (TST) model, acute administration 
of KEO-099 via intraperitoneal injection significantly decreased total time immobile relative to 
the saline group, suggesting a decrease in depression-related behavior in the KEO-099 treatment 
group [248]. Further studies suggested that these compounds may not produce inhibition of uptake-
1, since their binding affinities for SERT and NET were greater than 10 µM (Dr. Dukat laboratory, 
unpublished data). Quinazolines and guanidines are low molecular weight compounds and, based 
on their chemical structures, are protonated in the physiological environment. Thus, they might be 
OCT substrates or inhibitors and potentially possess antidepressant-like activities. To better 
understand the pharmacological action and mechanism of action of these compounds, we 
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examined the interaction of quinazolines with human (h)OCT1-3 and mOct1-3, to elucidate if 
OCTs are contributing to the pharmacological action of these compounds. Median effective dose 
(ED50) values of lead compounds were characterized for their in vivo CNS effects in mice by TST. 
Finally, a hOCT3 3-D homology model was constructed and docking studies were performed on 
selected compounds to better understand the interaction between hOCT3 and its substrates or 
inhibitors.   
7.B MATERIALS AND METHODS 
7.B.1 Chemicals      
Tritiated MPP+ ([3H]MPP+) and 5-hydroxytryptamine ([3H] 5-HT) were purchased from 
PerkinElmer Life and Analytical Science (Waltham, MA). Unlabeled MPP+, serotonin 
hydrochloride and imipramine hydrochloride was obtained from Sigma-Aldrich (Saint Louis, 
MO). Quinine monohydrochloride dihydrate was purchased from Acros Organics (Fair Lawn, NJ). 
Saline solution (0.9% sodium chloride) was purchased from Baxter, Inc. (Deerfield, IL). The seven 
quinazolines (GSW-286, KEO-093, KEO-099, OIA-008, KAI-333, MDA-049 and KAI-302) and 
six guanidines (KAI-323, MD-354, MDA-057, MDA-058, KAI-325 and KAI-324) were 
synthesized and provided by Dr. Dukat laboratory. Details of synthetic routes are not provided at 
this time. The chemical structures and physiochemical properties of quinazolines and guanidines 
were determined by SYBYL-X version 2.1 (Table 7.1).     
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       Quinazolines                         Guanidines 
 
Categories 
 
Compounds R1 R2 R3 MW pKaa cLogPa 
Rotatable 
Bondsa 
Quinazolines 
 
GSW-286 H H H 148.2 9.9 0.5 0 
 
KEO-093 H H Cl 182.6 9.1 1.2 0 
 
KEO-099 H Cl H 181.6 9.2 1.2 0 
 
OIA-008 Cl H H 182.6 9.2 1.2 0 
 
KAI-333 H F H 167.2 9.4 -0.3 0 
 
MDA-049 H CH3 H 162.2 9.8 1.0 0 
 
KAI-302 CH3 H H 163.2 9.8 1.0 0 
Guanidines 
 
KAI-323 H H H 136.2 10.9 -0.1 1 
 
MD-354 Cl H H 170.6 10.2 0.6 1 
 
MDA-057 H Cl H 169.6 10.2 0.6 1 
 
MDA-058 H CH3 H 150.2 10.8 0.4 1 
 
KAI-325 H  C(CH)3 H 192.3 10.5 1.8 1 
 
KAI-324 H CH2C6H5 H 226.3 9.5 2.0 3 
Table 7.1 Physicochemical properties of quinazolines and guanidines.   
a Values determined by SYBYL-X version 2.1.  
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7.B.2 Tissue Culture    
 Stably transfected human embryonic kidney 293 (HEK) cells expressing hOCT1 (HEK-
hOCT1), hOCT2 (HEK-hOCT2) hOCT3 (HEK-hOCT3), mOct1 (HEK-mOct1), mOct2 (HEK-
mOct2), or mOct3 (HEK-mOct3), as well as their corresponding empty vector transfected 
background control cell lines, were maintained at 37oC with 5% CO2 in DMEM high glucose 
media containing 10% serum and 1% Pen/Strep as described previously [14, 148, 250].   
7.B.3 Cell accumulation assays          
Cells were seeded into 24-well tissue culture plates at a density of 2×105 cells/well (without 
antibiotics) for 48 hours. On the day of the experiment, cells were preincubated in 500 μL transport 
buffer for 10 min and treated with unlabeled MPP+ (1 μM) spiked with [3H]MPP+ (0.25 μCi/mL) 
or unlabeled 5-HT spiked with [3H]serotonin (0.25 μCi/mL) in the presence of increasing 
concentrations (0.01 to 200 µM) of unlabeled test compounds for the times indicated. The 
radioactivity of cell lysate was quantified by liquid scintillation counting and normalized by total 
protein content in each well. Data were corrected for non-specific background in corresponding 
empty vector transfected cells. The half maximal inhibitory concentration (IC50) was calculated 
using nonlinear regression and the “log(inhibitor) vs. response” model using GraphPad Prism 
Software version 5.0 (GraphPad Software Inc., San Diego, CA). Substrate accumulation was 
reported as picomoles of substrate per milligram protein. Substrate concentration and 
accumulation time used for kinetic analysis of hOCT1, hOCT2, hOCT3, mOct1, mOct2 and mOct3 
(1 µM for MPP+ 1 min) were determined previously [3, 107]. The time-course profile for hOCT2-
mediated 5-HT accumulation was determined in this study. Experiments were repeated at least 
three times in triplicate and the results were reported as IC50 ± SEM.  Data in figures and reported 
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raw uptake scores were expressed as mean ± SD. Statistical differences were assessed using one-
way ANOVA followed by Dunnett’s t-test (α=0.05) for multiple post-hoc comparisons.   
7.B.4 Mode of inhibition for lead compounds  
The mode of inhibition of lead compounds was identified by mixed-model inhibition 
analysis in stably transfected hOCT2 and hOCT3 expressing cells, respectively. The following 
equations were used to assess the mode of inhibition:   
Vmax
app
=
Vmax
(1 + [I]/(α × ki))
 
Km
app
= Km
1 + [I]/ki
(1 + [I]/(α × ki))
 
Y =
Vmax
app
× [S]
Km
app
+ [S]
 
where Vmax is the maximum transport velocity in the absence of the inhibitor; Km is the Michaelis-
Menten constant for the substrate; ki is the inhibition constant estimated from data set under 
analysis; Y is the substrate uptake rate observed in the experiment; S and I are the concentration 
of substrate and inhibitor, respectively. The mode of inhibition is determined by the parameter α: 
if α value is greater than 1, it indicates competitive inhibition. Otherwise, it indicates the mode of 
inhibition is noncompetitive (α = 1) or uncompetitive (0< α < 1).  
In this study, the mode of inhibition experiments were performed under three independent 
conditions: no inhibitor, plus two different inhibitor concentrations. MPP+ uptake mediated by 
hOCT2 and hOCT3 in the presence and absence of selected inhibitors was plotted as a function of 
substrate concentration. All the data were corrected for background substrate accumulation in 
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empty vector control cells. Non-linear regression was used to fit the data into the equations shown 
above using GraphPad Prism Software version 5.0 (GraphPad Software Inc., San Diego, CA). The 
parameter, α, was used to determine the mode of inhibition for a representative compound.   
7.B.5. Mouse behavior assessment  
Male wild-type ICR mice (age 8 to 12 weeks) were purchased from Charles River 
Laboratories. Animals were maintained in temperature (25oC) and humidity-controlled (50–60%) 
rooms in groups of 4 – 5 with free access to food and water under a 12h/12h light/dark cycle.   
The TST were performed following the protocol of Steru et al and Yoshikawa et al with 
minor modifications [251, 252]. Briefly, mice were acclimated to the laboratory environment for 
3 hours before the experiment. Thirty minutes after intraperitoneal injection of saline or drug, the 
mice were individually suspended 60 cm above the laboratory bench by fixing their tails with 
adhesive tape to an acrylic bar. In dose-response studies, the wild-type mice received an 
intraperitoneal injection of a series of increasing doses of test compounds (0.1, 0.3, 1.0, 3.0, 10 
and 30 mg/kg). Saline, imipramine (20 mg/kg) and KEO-099 were used as controls. All behavioral 
experiments were performed blindly. The mice were filmed for 6 min and the recordings were 
stored for future analysis. Each recording was viewed three times and immobility time was scored 
(sec), providing a mean score for each animal. Tukey’s interquartile range was used to identify 
outliers in the dataset. Statistical differences were assessed using one-way ANOVA followed by 
Dunnett’s t-test (α=0.05) for multiple post-hoc comparisons.    
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7.B.6 hOCT3 homology modeling and docking studies       
hOCT3 homology models were constructed based on a comprehensive amino acid 
sequence alignment of hOCT3 with  Piriformospora indica high affinity phosphate transporter 
(PiPT, access number A8N031) [253-255]. The crystal structure of PiPT (PDB id 4J05) is currently 
recommended best template for OCTs [254]. The crystalized PiPT (resolution of 2.9 Å) was in an 
inward-facing occluded state with a bound phosphate in the membrane buried binding site [253]. 
The amino acid sequence alignment was performed using Clustal X. The homology model for 
hOCT3 was built using MODELLER (University of California at San Francisco, San Francisco, 
CA). MPP+ and 5 quinazolines (GSW-286, KEO-093, KEO-099, OIA-008 and MDA-049) were 
docked to the hOCT3 model using GOLD Suite (version 5.2). GOLD's default scoring function 
was used to score the ligand binding modes, and potential key amino acid residues were identified 
by analyzing the binding interaction energies. hOCT3 homology modeling and docking studies 
were done in collaborated with Dr. Dukat laboratory and Kavita Iyer.    
7.C Results 
7.C.1 Initial screening of quinazolines and guanidines as OCT inhibitors   
The inhibitory effects of quinazolines and guanidines were initially screened on three 
hOCTs and their murine orthologs using [3H]MPP+ as a prototypical substrate. Stably transfected 
hOCT1-expressing (HEK-hOCT1) cells showed marked accumulation of MPP+ (~33 fold) 
compared to empty vector transfected background control cells (139.8 ± 9.2 vs. 3.5 ± 0.1 pmol/mg 
protein/10 min, respectively; data not shown). HEK-mOct1 cells exhibited ~38.5 fold 
accumulation of MPP+ as compared to empty vector transfected background control cells (100.0 
± 8.2 vs. 2.6 ± 0.5 pmol/mg protein/10 min, respectively; data not shown). The known OCT 
inhibitor, quinine (200 µM), showed virtually complete inhibition of hOCT1- and mOct1-mediated 
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MPP+ uptake (>90% inhibition; Figure 7.1 A and B). The cell accumulation assay demonstrated 
that all test compounds (100 µM) except KAI-324 significantly inhibited hOCT1 activity (Figure 
7.1 A). In HEK-mOct1 cells, KEO-093, KEO-099, OIA-008, KAI-333, KAI-302, KAI-325 and 
KAI-324, each significantly inhibited mOct1 at 100 µM, while GSW-286, KAI-323, MD-354, 
MDA-057 and MDA-058 appeared to stimulate mOct1 transport activity and MDA-049 was 
without effect (Figure 7.1 B).      
The inhibitory effect of quinazolines and guanidines on hOCT2- and mOct2-mediated 
transport were examined next. Cellular accumulation of MPP+ was significantly increased in stably 
transfected hOCT2-expressing cells (~23 fold) as compared to background control (empty vector) 
cells (91.5 ± 5.7 vs. 3.9 ± 0.1 pmol/mg protein/10 min, respectively; data not shown). HEK-mOct2 
cells exhibited significantly higher accumulation of MPP+ (~23.7 fold) as compared to empty 
vector transfected background control cells (92.5 ± 1.3 vs. 3.9 ± 0.1 pmol/mg protein/10 min, 
respectively; data not shown). Quinine (200 µM) blocked (>85%) hOCT2- and mOct2-mediated 
MPP+ uptake (Figure 7.1 C and D). Similar to hOCT1, significant inhibition of hOCT2-mediated 
MPP+ transport was observed for all quinazolines and guanidines at 100 μM (Figure 7.1 C). All 
compounds except KAI-323 and MD-354 significantly inhibited mOct2-mediated MPP+ uptake 
(Figure 7.1 D).   
Stably transfected hOCT3-expressing (HEK-hOCT3) cells showed accumulation of MPP+ 
~30 fold greater than empty vector transfected background control cells (80.7 ± 8.1 vs. 4.4 ± 0.2 
pmol/mg protein/10 min; data not shown). Active transport was completely (95%) blocked by 
quinine at 200 µM and all quinazolines and guanidines at 100 μM (Figure 7.1 E and F). HEK-
mOct3 cells exhibited significantly higher accumulation of MPP+ (~23.7 fold) as compared to 
empty vector transfected background control cells (47.0 ± 3.6 vs. 1.2 ± 0.2 pmol/mg protein/10 
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min, respectively; data not shown). Marked inhibition of mOct3-mediated MPP+ transport by 
quinine was observed (Figure 7.1 F). In contrast to hOCT3, while all quinazolines significantly 
inhibited mOct3-mediated MPP+ uptake, only two guanidines, KAI-324 and KAI-325, 
significantly inhibited mOct3-mediated MPP+ uptake (Figure 7.1 F).      
7.C.2 Determination of IC50 values for quinazolines and guanidines    
Dose-response studies were conducted to estimate the IC50 values of quinazolines and 
guanidines for hOCT1, hOCT2 and hOCT3, as well as their murine orthologs (Figure 7.2, Table 
7.2). The IC50 values of quinazolines for hOCT1 were in the low micromolar range (1.3 µM to 
14.3 µM). The IC50 value of unsubstituted quinazoline GSW-286 for hOCT1 was estimated as 
14.3 ± 2.2 µM, which is 2-11 fold higher than substituted quinazolines (KEO-093, KEO-099, OIA-
008, KAI-333, MDA-049 and KAI-302). In addition, the IC50 values of six guanidines for hOCT1 
ranged from 0.9 µM to 761.9 µM. The IC50 value of unsubstituted guanidine KAI-323 for hOCT1 
was estimated as 41.1 ± 14.4 µM, which is 3 fold greater than unsubstituted quinazoline GSW-
286. Similar to quinazolines, the IC50 values of unsubstituted guanidine KAI-323 for hOCT1 were 
3–46 fold higher than some substituted guanidines including MDA-057, MD-354, MDA-058 and 
KAI-325. However, the IC50 value for benzyl substituted guanidine KAI-324 was determined as 
761.9 ± 254.7 µM, which was 19 fold greater than that for unsubstituted guanidine KAI-323. 
Species differences were observed between hOCT1 and mOct1. In general, lower inhibitory effects 
of quinazolines and guanidines were observed for mOct1 (greater IC50 values) as compared to 
hOCT1 (Table 7.2).     
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Figure 7.1 Inhibition profiles of quinazolines and guanidines on OCTs.  
 
Inhibition of (A) hOCT1-, (B) mOct1-, (C) hOCT2-, (D) mOct2-, (E) hOCT3- and (F) mOct3-
mediated MPP+ uptake by quinazolines (blue, 100 μM), guanidines (yellow, 100 μM) and quinine 
(black, 200 μM). The concentration of MPP+ was 1 μM, incubation time was 10 min, and data 
shown were corrected for non-specific background. Values are mean ± SD of triplicate values. *** 
denotes p < 0.001 as determined by one-way ANOVA followed by Dunnett’s t-test.   
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The IC50 values of substituted quinazolines (KEO-093, KEO-099, OIA-008, KAI-333, 
MDA-049 and KAI-302) for hOCT2 ranged from 9.0-26.4 µM, which are lower (higher affinity) 
than that for unsubstituted quinazoline GSW-286 (46.5 ± 0.6 µM). Similarly, chloride, methyl and 
t-butyl substituted guanidines (MDA-057, MDA-058 and KAI-325) exhibited 1.5-10 fold lower 
IC50 values for hOCT2 than that for unsubstituted guanidine KAI-323 (89.0 ± 12.2 µM). However, 
benzyl substituted guanidine KAI-324 was not significantly different from unsubstituted guanidine 
KAI-323. In addition, it was also observed that unsubstituted quinazoline GSW-286 has a lower 
IC50 value for hOCT2 than unsubstituted guanidine KAI-323. The IC50 values of the quinazolines 
and guanidines for hOCT2 were similar to that for mOct2 (Table 7.2). The IC50 values of KAI-323 
and MD-354 for mOct2 were not determined since they failed to show significant inhibition on 
mOct2 during the initial screening.   
Dose-response studies for hOCT3 and mOct3 indicated that unsubstituted quinazoline 
GSW-286 exhibited 2-26 fold higher IC50 values for hOCT3 than substituted quinazolines KEO-
093, KEO-099, OIA-008, KAI-333, MDA-049 and KAI-302. In particular, OIA-008, KAI-333 
and KAI-302 demonstrated highest affinity for hOCT3 among all test compounds with IC50 values 
in the nanomolar range. In addition, the IC50 value for unsubstituted guanidine KAI-323 was 
approximately 8 fold greater than that for unsubstituted quinazoline GSW-286 (99.8 ± 2.8 µM vs. 
12.2 ± 1.9 µM). Benzyl substituted guanidine KAI-324 exhibited the lowest IC50 value for hOCT3 
among all test compounds. Species differences were also observed between hOCT3 and mOct3 
cells. KEO-093, KEO-099, OIA-008, KAI-333, MDA-049, KAI-302 and KAI-325 demonstrated 
3-120 fold lower IC50 values for hOCT3 than that for mOct3.     
With the notable exception of KAI-324, all other test quinazolines showed preferential 
affinity for hOCT1 and hOCT3 as compared to hOCT2. In general, chloride, fluoride, methyl and 
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t-butyl substituted quinazolines and guanidines demonstrated decreased IC50 values (higher 
affinity) for hOCT1, hOCT2 and hOCT3, while benzyl substituted guanidine exhibited a higher 
IC50 values (poorer affinity) for hOCT1 and hOCT3.  
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Table 7.2 IC50 values of test compounds for hOCT1, hOCT2, hOCT3 and their murine orthologs.     
 Compounds 
IC50a (µM) 
hOCT1 hOCT2 hOCT3 mOct1 mOct2 mOct3 
Quinazolines 
GSW-286 14.3 ± 2.2 46.5 ± 0.6 12.2 ± 1.9 NDb 31.8 ± 1.3 18.8 ± 2.3 
KEO-093 4.8 ± 0.7 9.0 ± 1.2 5.9 ±  2.3 38.2 ± 9.3 6.2 ± 0.5 15.9 ± 3.1 
KEO-099 3.0 ± 0.5 16.4 ±  2.7 3.9 ± 1.4 40.7 ± 13.7 13.0 ± 0.8 30.3 ± 13.0 
OIA-008 2.3 ± 0.5 13.3 ±  4.0 0.9 ± 0.1 45.2 ± 9.4 16.1 ± 5.5 13.9 ± 1.4 
KAI-333 1.3 ± 0.1 11.9 ± 0.2 0.47 ± 0.01 92.8 ± 1.1 19.2 ± 5.4 19.3 ± 4.3 
MDA-049 8.2 ± 2.2 12.1 ± 0.3 2.0 ± 0.4 ND 15.0 ± 0.5 12.7 ± 2.4 
KAI-302 4.6 ± 0.6 26.4 ± 0.7 0.46 ± 0.02 69.2  ± 2.6 50.7 ± 7.5 56.3 ± 14.6 
Guanidines 
KAI-323 41.1 ± 14.4 89.0 ± 12.2 99.8 ± 2.8 ND ND ND 
MDA-057 10.0 ± 0.6 18.9 ± 0.1 2.8 ± 0.7 ND 14.2 ± 0.4 ND 
MD-354 13.7 ± 0.8 60.5 ± 4.1 7.6 ± 0.7 ND ND ND 
MDA-058 10.0 ± 0.2 9.3 ± 4.8 4.6 ± 1.1 ND 22.1 ± 2.4 ND 
KAI-325 0.9 ± 0.2 8.3 ± 3.9 2.2 ± 0.2 18.3 ± 1.0 5.0 ± 1.0 46.0 ± 2.1 
KAI-324 762 ± 255 96.2 ± 8.0 452.5 ± 87.9 82.0 ± 0.9 92.5 ± 4.3 492 ± 128 
a IC50 values were expressed as
 mean ± SEM from triplicate determinations.  
b ND, not determined.   
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Figure 7.2 (A) Dose-response curves for quinazolines and guanidines on hOCT1.  
 
Representative data showing 1 min uptake of MPP+ (1 µM) measured in HEK-hOCT1 cells 
in the presence of increasing concentrations of quinazolines and guanidines (10-9 to 10-3 M) 
are shown. Data were corrected for nonspecific background measured in the empty vector 
control cells and are means ± SD of triplicate values. IC50 values were determined with 
nonlinear regression and the “log(inhibitor) versus response” model using GraphPad Prism 
software. 
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Figure 7.2 (B) Dose-response curves for quinazolines and guanidines on mOct1.  
 
Representative data showing 1 min uptake of MPP+ (1 µM) measured in HEK-mOct1 cells 
in the presence of increasing concentrations of quinazolines and guanidines (10-7 to 10-2.7 
M) are shown. Data were corrected for nonspecific background measured in the empty 
vector control cells and are means ± SD of triplicate values. IC50 values were determined 
with nonlinear regression and the “log(inhibitor) versus response” model using GraphPad 
Prism software. 
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Figure 7.2 (C) Dose-response curves for quinazolines and guanidines on hOCT2.  
 
Representative data showing 1 min uptake of MPP+ (1 µM) measured in HEK-hOCT2 cells 
in the presence of increasing concentrations of quinazolines and guanidines (10-8 to 10-2.3 
M) are shown. Data were corrected for nonspecific background measured in the empty 
vector control cells and are means ± SD of triplicate values. IC50 values were determined 
with nonlinear regression and the “log(inhibitor) versus response” model using GraphPad 
Prism software.  
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Figure 7.2 (D) Dose-response curves for quinazolines and guanidines on mOct2.    
 
Representative data showing 1 min uptake of MPP+ (1 µM) measured in HEK-mOct2 cells 
in the presence of increasing concentrations of quinazolines and guanidines (10-7 to 10-2.7 
M) are shown. Data were corrected for nonspecific background measured in the empty 
vector control cells and are means ± SD of triplicate values. IC50 values were determined 
with nonlinear regression and the “log(inhibitor) versus response” model using GraphPad 
Prism software.    
 
 
 
113 
 
 
 
0
50
100
-9 -8 -7 -6 -5 -4 -3 -2Control
log [GSW-286] M
M
P
P
+
 u
p
ta
k
e
(%
 o
f 
c
o
n
tr
o
l)
0
50
100
-9 -8 -7 -6 -5 -4 -3Control
log [KEO-093] M
M
P
P
+
 u
p
ta
k
e
(%
 o
f 
c
o
n
tr
o
l)
0
50
100
-9 -8 -7 -6 -5 -4 -3Control
log [KEO-099] M
M
P
P
+
 u
p
ta
k
e
(%
 o
f 
c
o
n
tr
o
l)
0
50
100
-9 -8 -7 -6 -5 -4 -3Control
log [OIA-008] M
M
P
P
+
 u
p
ta
k
e
(%
 o
f 
c
o
n
tr
o
l)
0
50
100
150
-9 -8 -7 -6 -5 -4Control
log [KAI-333] M
M
P
P
+
 u
p
ta
k
e
(%
 o
f 
c
o
n
tr
o
l)
0
50
100
-9 -8 -7 -6 -5 -4Control
log [MDA-049] M
M
P
P
+
 u
p
ta
k
e
(%
 o
f 
c
o
n
tr
o
l)
0
50
100
150
-9 -8 -7 -6 -5 -4Control
log [KAI-302] M
M
P
P
+
 u
p
ta
k
e
(%
 o
f 
c
o
n
tr
o
l)
0
50
100
-7 -6 -5 -4 -3 -2Control
log [KAI-323] M
M
P
P
+
 u
p
ta
k
e
(%
 o
f 
c
o
n
tr
o
l)
0
50
100
-9 -8 -7 -6 -5 -4Control
log [MDA-057] M
M
P
P
+
 u
p
ta
k
e
(%
 o
f 
c
o
n
tr
o
l)
0
50
100
-8 -7 -6 -5 -4 -3 -2Control
log [MD-354] M
M
P
P
+
 u
p
ta
k
e
(%
 o
f 
c
o
n
tr
o
l)
0
50
100
-8 -7 -6 -5 -4Control
log [MDA-058] M
M
P
P
+
 u
p
ta
k
e
(%
 o
f 
c
o
n
tr
o
l)
0
50
100
-8 -7 -6 -5 -4 -3 -2Control
log [KAI-325] M
M
P
P
+
 u
p
ta
k
e
(%
 o
f 
c
o
n
tr
o
l)
0
50
100
-6 -5 -4 -3 -2Control
log [KAI-324] M
M
P
P
+
 u
p
ta
k
e
(%
 o
f 
c
o
n
tr
o
l)
 
Figure 7.2 (E) Dose-response curves for quinazolines and guanidines on hOCT3.  
 
Representative data showing 1 min uptake of MPP+ (1 µM) measured in HEK-hOCT3 cells 
in the presence of increasing concentrations of quinazolines and guanidines (10-8 to 10-2.7 
M) are shown. Data were corrected for nonspecific background measured in the empty 
vector control cells and are means ± SD of triplicate values. IC50 values were determined 
with nonlinear regression and the “log(inhibitor) versus response” model using GraphPad 
Prism software.  
 
 
114 
 
0
50
100
-8 -7 -6 -5 -4 -3Control
log [GSW-286] M
M
P
P
+
 u
p
ta
k
e
(%
 o
f 
c
o
n
tr
o
l)
0
50
100
150
-7 -6 -5 -4 -3Control
log [KEO-093] M
M
P
P
+
 u
p
ta
k
e
(%
 o
f 
c
o
n
tr
o
l)
0
50
100
-7 -6 -5 -4 -3Control
log [KEO-099] M
M
P
P
+
 u
p
ta
k
e
(%
 o
f 
c
o
n
tr
o
l)
0
50
100
-7 -6 -5 -4 -3Control
log [OIA-008] M
M
P
P
+
 u
p
ta
k
e
(%
 o
f 
c
o
n
tr
o
l)
0
50
100
-8 -7 -6 -5 -4 -3Control
log [KAI-333] M
M
P
P
+
 u
p
ta
k
e
(%
 o
f 
c
o
n
tr
o
l)
0
50
100
-8 -7 -6 -5 -4 -3Control
log [MDA-049] M
M
P
P
+
 u
p
ta
k
e
(%
 o
f 
c
o
n
tr
o
l)
0
50
100
-8 -7 -6 -5 -4 -3Control
log [KAI-333] M
M
P
P
+
 u
p
ta
k
e
(%
 o
f 
c
o
n
tr
o
l)
0
50
100
-8 -7 -6 -5 -4 -3Control
log [KAI-325] M
M
P
P
+
 u
p
ta
k
e
(%
 o
f 
c
o
n
tr
o
l)
0
50
100
-6 -5 -4 -3 -2Control
log [KAI-324] M
M
P
P
+
 u
p
ta
k
e
(%
 o
f 
c
o
n
tr
o
l)
 
Figure 7.2 (F) Dose-response curves for quinazolines and guanidines on mOct3.   
 
Representative data showing 1 min uptake of MPP+ (1 µM) measured in HEK-mOct3 cells 
in the presence of increasing concentrations of quinazolines and guanidines (10-7 to 10-2.7 
M) are shown. Data were corrected for nonspecific background measured in the empty 
vector control cells and are means ± SD of triplicate values. IC50 values were determined 
with nonlinear regression and the “log(inhibitor) versus response” model using GraphPad 
Prism software.  
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7.C.3 Inhibition potencies of KEO-099 for hOCT2-mediated 5-HT uptake    
The inhibitory effect of KEO-099 on transport activity of hOCT2 was further 
assessed using 5-HT as the substrate. Time-course studies were performed to assess the 
initial rate period for hOCT2-mediated 5-HT uptake. The initial phase was defined as the 
period where uptake rate increased linearly with time. The results demonstrated that 
hOCT2-mediated uptake was linear for at least the first 5 min (Figure 7.3), therefore a 3 
min incubation time was used in all kinetic studies. Dose-response studies were performed 
to determine the Km value of 5-HT for hOCT2. Increased 5-HT accumulation in hOCT2-
expressing cells was observed in the presence of increasing concentrations of substrate 
(Figure 7.3). The curve was fit to the Michaelis-Menten equation, and the estimated Km 
value for 5-HT on hOCT2 was 227 ± 4 µM.  
The inhibitory effect of KEO-099 on monoamine uptake mediated by hOCT2 was 
then evaluated using [3H]serotonin. Quinine (200 µM) and KEO-099 (100 µM) 
significantly inhibited hOCT2-meidated 5-HT uptake (Figure 7.4 A). In the presence of 
increasing concentrations of KEO-099 (0.01-1000 µM), decreased transport activity for 
hOCT2 was observed (Figure 7.4 B). The IC50 value of KEO-099 for hOCT2 was estimated 
as 0.56 ± 0.08 µM, respectively.        
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Figure 7.3 hOCT2-mediated 5-HT and MPP+ uptake.   
 
(A) Time-dependent uptake of 5-HT by hOCT2. Time-dependent experiments were 
conducted for up to 30 min. The concentration of 5-HT was 1 µM. (B) Michaelis-Menten 
kinetics of 5-HT transport in hOCT2 cells. The concentration of 5-HT was 1 µM, and the 
uptake was measured for 3 min at room temperature. (C) Michaelis-Menten kinetics of 
MPP+ transport in hOCT2 cells. The concentration of MPP+ was 1 µM, and the uptake was 
measured for 1 min at room temperature. Substrate uptake was background corrected by 
subtracting the non-specific uptake as measured in the HEK-empty vector cells. The 
Michaelis constant (Km) value was calculated by nonlinear regression using the Michaelis-
Menten model.      
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Figure 7.4 Inhibition of hOCT2-mediated 5-HT uptake by KEO-099.    
 
(A) Inhibition of hOCT2-mediated 5-HT uptake by KEO-099 (100 μM) and quinine (200 
μM). The concentration of 5-HT was 1 μM, incubation time was 10 min, and data shown 
were corrected for non-specific background. *** denotes p < 0.001 as determined by one-
way ANOVA followed by Dunnett’s t-test. (B) Dose-response curve for KEO-099 on 
hOCT2. Representative data showing 3 min uptake of 5-HT (1 µM) measured in hOCT2 
cells in the presence of increasing concentrations of KEO-099 (10-8 to 10-4 M) are shown. 
Data were corrected for nonspecific background measured in the empty vector control cells 
and are means ± SD of triplicate values. IC50 values were determined with nonlinear 
regression and the “log(inhibitor) versus response” model using GraphPad Prism software.  
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7.C.4 Mode of inhibition for hOCT2 and hOCT3  
To properly interpret the inhibition and subsequent modeling and quantitative 
structure activity relationship (QSAR) study data, the mode of inhibition between OCT 
substrate and the inhibiting quinazoline and guanidine compounds must be determined. 
MPP+ accumulation was linear for at least 1 min and the Km values were determined as 6.9 
µM and 32.1 µM for hOCT2 and hOCT3, which are comparable to the reported values in 
the literature [3]. Therefore, saturation analysis studies were performed for hOCT2 and 
hOCT3 in the absence and presence of two different concentrations of representative 
quinazoline (KEO-099) and guanidine (MDA-057 and KAI-325) compounds. Substrate 
uptake curves were fit to the equations for mixed-model inhibition, and α values were 
calculated for each compound. All estimated α values were greater than 1, indicating that 
KEO-099, MDA-057 and KAI-325 were competitive inhibitors of hOCT2- and hOCT3-
mediated transport (Table 7.3).       
 
 
 
Table 7.3 Estimated α values from mixed-model inhibition analysis.    
 
Compound hOCT2 hOCT3 
KEO-099 24.6 25.1 
MDA-057 34.0 23.0 
KAI-325 7.8 17.5 
Quinine 6.5 3.9 
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7.C.5 Mouse behavior studies   
Three compounds, KEO-099, GSW-286 and MDA-057, were selected as lead 
compounds based on in vitro data. The ED50 value for KEO-099 was determined as 0.23 
mg/kg previously [248]. In this study, imipramine (20 mg/kg) significantly decreased the 
total time spent immobile during 6 min measurement in the TST as compared to the saline 
group (57.6 ± 7.5 seconds vs 6.9 ± 2.9 seconds, Figure 7.5). The antidepressant-like activity 
for KEO-099 was confirmed, as KEO-099 (1 mg/kg) significantly reduced the total time 
spent immobile to 2.8 ± 0.8 seconds. However, unsubstituted quinazoline GSW-286 (0.1 – 
30 mg/kg) did not produce a significant decrease in the total time immobile during the TST 
as compared to the saline group (Figure 7.5). Although the chloride substituted guanidine 
MDA-057 decreased the total time spent immobile in the TST at 3 mg/kg (57.63 ± 7.52 vs. 
24.0 ± 8.5), no statistical differences were observed in the ANOVA test due to the large 
experimental error. The other doses of MDA-057 did not significantly change the total time 
spent immobile in the TST (Figure 7.5).     
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Figure 7.5 Tail suspension test for KEO-099, GSW-286 and MDA-057.  
Upper panel: total time spent immobile after administration of imipramine (20 mg/kg), 
KEO-099 (1 mg/kg) and different doses of GSW-286. Lower panel: total time spent 
immobile after administration of imipramine (20 mg/kg), KEO-099 (1 mg/kg) and different 
doses of MDA-057. Effects are reported as mean ± SEM (second) in the mouse TST (n = 
8 – 11 mice/treatment). Asterisk (***) denotes a significant difference compared to saline 
group (p < 0.05).    
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7.C.6 Homology modeling and docking studies for hOCT3  
The amino acid sequence of hOCT3 (UniProt: O75751) and the approximate 
location of the predicted transmembrane domains were obtained from the literature [256, 
257]. The amino acid sequence and predicted transmembrane domains of PiPT were 
obtained from PDB (PDB:4J05, accession number: A8N031). Clustal X was used to align 
the peptide sequences between hOCT3 and PiPT. A total of 100 homology models of 
hOCT3 were constructed using MODELLER v9.12 (University of California at San 
Francisco, San Francisco, CA). The best model was selected and the loops and side chains 
were refined by MODELLER (Figure 7.6).   
The conformation and charge distribution of MPP+ and quinazolines were 
optimized with energy minimization using tripos force field with Gasteiger–Hückel 
charges in SYBYL-X 2.1. MPP+ docked to hOCT3 through 100 iterations using 
GOLDSuite 5.2 and GOLD's default scoring function was utilized to select binding modes. 
The results obtained were analyzed by cluster analysis to find the modes exhibiting similar 
docking poses, and two plausible binding modes were identified (Figure 7.6). Quinazolines 
were further docked into the substrate binding site of hOCT3, and the critical amino acid 
residues that interacted with MPP+ and quinazolines were identified (Figure 7.7 and Table 
7.4). The results suggested that guanidine N-atoms of quinazolines interacted with D478 
(TM11) through a salt-bridge interaction, and the guanidine moiety of quinazolines 
interacted with the aromatic rings of W223 (TM4) and F165 (TM2) through a cation-π 
interaction. In addition, hydrophobic interactions were observed for the substituted group 
of quinazolines with the following amino acid residues: KEO-099 and MDA-049 with 
A362, Y365 and Q366 and OIA-008 and GSW-286 with A362.          
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Figure 7.6 The homology models of hOCT3 and two modes of binding for MPP+.  
The homology models of hOCT3 were constructed using the crystal structure of inward-
facing conformation of PiPT (PDB number: 4J05). This model was done in collaboration 
with Dr. Dukat laboratory and Kavita Iyer.   
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Figure 7.7 Docking the quinazolines into the binding pocket of hOCT3.  
 
Ionic bond interactions are indicated by red dotted lines. Orange: KEO-099; pale green: 
OIA-008; magenta: GSW-286; cyan: KEO-093; red: MDA-049. This model was done in 
collaboration with Dr. Dukat laboratory and Kavita Iyer. 
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Table 7.4 Summary of key amino acid residues identified in docking studies of 
quinazolines on hOCT3.    
 
Quinazolines Interactions Amino acids 
GSW-286 
Ionic salt-bridge 
Cation-π 
Hydrophobic 
D478 
F165 and W223 
A362 
KEO-093 
Ionic salt-bridge 
Cation-π 
Hydrophobic 
D478 
F165 and W223 
L23 
KEO-099 
Ionic salt-bridge 
Cation-π 
Hydrophobic 
D478 
F165 and W223 
A362, Y365and Q366 
OIA-008 
Ionic salt-bridge 
Cation-π 
Hydrophobic 
D478 
F165 and W223 
A362 
MDA-049 
Ionic salt-bridge 
Cation-π 
Hydrophobic 
D478 
F165 and W223 
A362, Y365, Q366 
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7.D DISCUSSION      
According to the global burden of disease study 2010, depression is the fourth 
leading cause of illness-induced disability, and it is predicted that depression will reach 
second place by 2020 [258]. Although a number of drugs are used clinically in the treatment 
of depression, approximately one-half of depressed patients failed to find relief using 
current therapies, especially in mild or moderate cases of depression [243, 245-247]. This 
may be due to the presence of multiple clearance pathways for monoamine 
neurotransmitters in brain subject to different modes of regulation. Undesirable side effects, 
such as weight loss, increased bone fracture risk and gastrointestinal effects, are also often 
observed in the clinical application of antidepressants [244]. Thus, there is an unmet need 
to develop antidepressants with a novel mechanism of action and greater efficacy than 
existing antidepressants. Recently, hOCT2 and hOCT3 have been discovered as key 
components of uptake-2 and suggested to play an important role in regulating 
neurotransmitter clearance in brain [91, 92]. In addition, a number of antidepressants 
currently in use, such as fluoxetine, desipramine and sertraline, are now known to be 
effective OCT inhibitors in vitro [259, 260]. Currently, it remains unclear what, if any, role 
OCTs may have in their therapeutic action of these compounds, however, together these 
data suggest OCTs may be viable therapeutic targets in depression. Certainly, at a 
minimum, an impact on CNS clearance appears likely.   
The quinazoline and guanidine compounds examined in this study are a novel series 
of compounds developed as potential novel therapeutic agents for depression [248]. 
Although their binding affinities for SERT and NET were greater than 10 µM, a chloride 
substituted quinazoline demonstrated potent antidepressant-like effects in mice [248]. In 
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the present study, the interactions of thirteen quinazoline and guanidine compounds with 
OCTs were studied. The inhibitory effects of the quinazoline and guanidine compounds 
varied according to the modification of their structures. Overall, hOCT2 was least sensitive 
to inhibition, with the notable exception of the benzyl substituted guanidine KAI-324 
which exhibited 5-8 fold higher affinity for hOCT2 over hOCT1 and 3 (Table 7.2).   
Guanidine compounds lack the methylene bridge structure in the quinazoline ring, 
and have a rotatable bond between the guanidino group and the phenyl group (Table 7.1). 
Unsubstituted guanidine (KAI-323) had a poor affinity (higher IC50 value) for hOCT1-3 as 
compared to unsubstituted quinazoline (GSW-286), indicating that the flexible open ring 
structure of guanidine compounds was unfavorable for interaction with hOCT1-3. In 
addition, substituting R1-R3 positions of quinazoline and guanidine compounds with 
different functional groups changed their inhibitory effects for hOCTs. Chloride and 
fluoride are electron withdrawing groups, while methyl, t-butyl and benzyl are electron 
donating groups. However, both electron withdrawing groups (i.e., chloride and fluoride) 
and electron donating groups (i.e., methyl and t-butyl) increased the affinities of 
quinazoline and guanidine compounds for hOCT1-3 as compared to the unsubstituted 
compounds. These results indicated that steric effects, rather than polar effects, impact the 
affinity of quinazolines and guanidines for hOCTs. It was also observed that R1 is the most 
favorable substitution position for quinazoline compounds for hOCT3, as both chloride 
and methyl substituted quinazolines at R1 position exhibited 4-6 fold increased inhibitory 
effects (lower IC50 values) for hOCT3 as compared to those for R2 and R3 substituted 
compounds. On the contrary, a large benzyl group (KAI-324) decreased the inhibitory 
effects of guanidine compounds for hOCT1 and hOCT3, possibly due to the unfavorable 
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steric effects. Although the affinity of this compound for hOCTs overall is somewhat poor, 
its in vitro profile suggests it to be a hOCT2-selective inhibition and this is being 
investigated further. Both species similarities and differences were observed between 
human and mouse OCT orthologs. In general, murine orthologs were less sensitive to 
inhibition by the test compounds as compared to human (Table 7.2). The IC50 values of 
quinazoline and guanidine compounds for mOct2 were comparable (0.6 to 2.3 fold) to 
those for hOCT2, whereas relatively weaker inhibitory effects were observed for mOct1 
and mOct3 than those for hOCT1 and hOCT3, i.e. there was no trend for mOct2 to be less 
sensitive to inhibition as compared to mOct1 an dmOct3.     
Three lead compounds, KEO-099, GSW-286 and MDA-057 were selected for in 
vivo testing based on in vitro inhibitory profiles. KEO-099 is the chloride substituted 
quinazoline. GSW-286 is the unsubstituted quinazoline, and MDA-057 is the chloride 
substituted guanidine. The in vitro inhibitory effect of KEO-099 vs. 5-HT for hOCT2 was 
~30 fold stronger (lower IC50 value) than that determined using MPP
+, indicating that a 
nanomolar level of lead compound might provide sufficient inhibition on uptake-2 in vivo. 
KEO-099 exhibited potent antidepressant-like effects in the TST with ED50 value 
determined as low as 0.23 mg/kg [248]. However, unsubstituted quinazoline and chloride 
substituted guanidine failed to show significant CNS pharmacological effects in the TST 
(Figure 7.5), suggesting that both substitution groups and the methylene bridge might be 
important for the pharmacological effects of these compounds. Further pharmacological 
and pharmacokinetic studies should be performed on KEO-099 as well as other compounds.            
To provide hOCT structural information to our data interpretation, we constructed 
a 3-D homology models for hOCT3 and performed docking studies for MPP+ and 
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quinazolines. The protein structures of OCTs are not available due to the difficulties 
associated with crystallization of membrane proteins. A high-resolution crystal structure 
of PiPT was used as the template which shared 21% amino acid sequence similarity with 
hOCT3 [253-255]. As compared with Lactose Permease transporter used previously for 
OCT homology models, PiPT and OCTs belong to the same major facilitator superfamily 
and share a higher amino acid sequence similarity [254-256]. A central binding pocket in 
hOCT3 was chosen for both MPP+ and quinazolines, since quinazolines demonstrated a 
competitive mode of inhibition on hOCT3 (Figure 7.7, Table 7.2). The homology modeling 
studies suggested that hOCT3 interacted with docked compounds through TMDs 1, 2, 4, 7 
and 11. A number of potential key amino acid residues in hOCT3 were identified: F165, 
W223, A362, Y365, Q366 and D478. Whether these residues truly represent transporter-
substrate contact points requires further investigation.                 
In summary, thirteen quinazolines and guanidines were identified as potent 
inhibitors for hOCTs/mOcts. The inhibitory effects of quinazolines and guanidines with 
hOCTs/mOcts were compared and lead compounds were selected based on in vitro profiles. 
KEO-099 demonstrated potent antidepressant-like effects in the TST, while GSW-286 and 
MDA-057 failed to show antidepressant-like activities. This study suggested that novel 
OCT inhibitors such as quinazolines have the potential to possess antidepressant-like 
effects even if they did not target SERT or NET. In addition, we performed the homology 
modeling and docking studies for hOCT3. The mode of inhibition studies showed that 
representative quinazoline and guanidine compounds competed for the same binding 
pocket with MPP+ in hOCT2 and hOCT3. The homology models of hOCT3 were 
developed, and several amino acid residues were identified by docking studies. This 
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homology model of hOCT3 could be further used to support 3-D QSAR for designing the 
next generation of quinazolines and guanidines.            
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CHAPTER 8 
 
 
OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
 
 
A major function of the polyspecific organic cation OCTs/OATs (SLC22 
transporter family) is to exert selection control over the influx of small molecules across 
cell membranes [2, 3, 6]. Since OCTs/OATs are widely expressed in various peripheral 
barrier organs, they contribute to the uptake into and secretion from enterocytes, 
hepatocytes renal proximal tubular cells for a broad variety of endogenous and exogenous 
compounds [2, 3, 6]. The activity of OCTs/OATs can be altered by a second drug via 
inhibition, and thus drug-drug interaction may occur during combination therapy when 
transporter substrates and inhibitors are administered together [191]. In addition, 
hOCT2/mOct2 and hOCT3/mOct3 are highly expressed in neurons and glial cells in brain, 
and many monoamine neurotransmitters including serotonin (5-HT), norepinephrine (NE) 
and dopamine (DA) are their substrates [52, 91, 92]. Thus, OCTs appear to be an important 
component of uptake-2 and may participate in the regulation of neurotransmitter clearance 
in the central nervous systems (CNS). In this study, we began to explore the potential role 
of OCT inhibitors in mood disorders, as well as the roles of OCTs/OATs in drug 
transporter-mediated drug-drug interaction.     
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Despite widespread multimorbidity, most clinical therapeutic guidelines are written 
based on the condition of a single disease and the impact of applying complex multiple 
drug regimens during polypharmacy is generally not well understood. The potential for 
transporter mediated drug-drug interactions (DDIs) during combination therapy can be 
assessed by in vitro drug transporter expressing cell models [129]. In chapter 3 to chapter 
5, we investigated the inhibitory effects of five different drugs on OCTs and OATs and 
evaluate their potential in transporter-mediated DDIs. Rhein, a major metabolite of the 
prodrug diacerein and a major component of the medicinal herb Rheum sp., is used for its 
beneficial effects in a variety of clinical applications including the treatment of 
osteoarthritis and diabetic nephropathy [116-119]. In chapter 3, the inhibitory effects of 
rhein on hOAT1, hOAT3, hOAT4, and mOat1 and mOat3 were examined in heterologous 
cell lines stably expressing each transporter in isolation. Rhein was shown to potently 
inhibit hOAT1 and hOAT3, with IC50 estimates in the low nanomolar range (IC50 = 77.1 ± 
5.5 nM and 8.4 ± 2.5 nM, respectively), while poor affinity was observed for hOAT4 (IC50 > 
100 mM). Marked species differences were observed with hOAT1 and hOAT3 exhibiting 
3- and 28-fold higher affinity for rhein as compared to their murine orthologs. The 
estimated DDI indices (>>0.1) indicated a very strong potential for clinically relevant, 
rhein perpetrated DDIs mediated by inhibition of hOAT1 (DDI index = 5.0; 83% inhibition) 
and/or hOAT3 (DDI index = 46; 98% inhibition) transport activity. These results suggested 
that rhein, from herbal medicines and/or prodrug conversion, may significantly impact the 
dosing, efficacy and toxicity (i.e., pharmacokinetics and pharmacodynamics) of co-
administered hOAT1 and/or hOAT3 drug substrates. 
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Tuberculosis is a serious and worldwide disease that infect ~9 million people and 
causes about 1.4 million deaths every year [136]. Moreover, the frequency of comorbidity 
with HIV and with diabetes is on the rise, increasing the risk of these patients for 
experiencing DDIs due to polypharmacy [154]. Ethambutol, a first-line antituberculosis 
drug, is an organic cation at physiological pH, and its major metabolite, EDA, is 
zwitterionic [145]. In chapter 4, we assessed the effects of ethambutol and 2,2’-
(ethylenediimino)dibutyric acid (EDA) on the function of hOCT1, hOCT2, and hOCT3 
and that of EDA on hOAT1 and hOAT3. Potent inhibition of hOCT1- and hOCT2-
mediated transport by ethambutol was observed, and IC50 values of ethambutol were 
determined as 92.6 ± 10.9 and 253.8 ± 90.8 µM for hOCT1 and hOCT2, respectively. 
Ethambutol exhibited much weaker inhibition of hOCT3 (IC50 = 4.1 ± 1.6 mM); however, 
significant inhibition (>80%) was observed at physiologically relevant concentrations in 
the GI tract after oral dosing. EDA failed to exhibit any inhibitory effects that warranted 
further investigation. DDI analysis indicated a strong potential for ethambutol interaction 
on hOCT1 expressed in enterocytes and hepatocytes and on hOCT3 in enterocytes, which 
would alter absorption, distribution, and excretion of coadministered cationic drugs, 
suggesting that in vivo pharmacokinetic studies are necessary to confirm drug safety and 
efficacy. In particular, TB patients with coexisting HIV or diabetes might experience 
significant DDIs in situations of coadministration of ethambutol and clinical therapeutics 
known to be hOCT1/ hOCT3 substrates, such as lamivudine or metformin. 
The alkaloids matrine and oxymatrine are widely used in herbal medicine for the 
treatment of cancer, as well as viral, and cardiac diseases [179-182]. Their physicochemical 
properties indicated that they are potential inhibitors for hOCTs, leading to drug–drug 
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interactions. In chapter 5, we assessed the inhibitory effects of matrine and oxymatrine on 
the function of hOCT1, hOCT2 and hOCT3 using stably transfected transporter-expressing 
cells. At 100-fold excess, oxymatrine exhibited marked inhibition of hOCT1-mediated 
substrate uptake, while matrine failed to produce significant inhibition on hOCT1. The IC50 
value for oxymatrine on hOCT1 was estimated as 513 ± 132 μM. While there was no 
significant inhibition of hOCT2 or hOCT3 at 100-fold excess, oxymatrine and matrine 
showed 42% and 88% inhibition of hOCT3-mediated substrate uptake at 3 and 6 mM, 
respectively. Considering the potential intestinal lumen and reported plasma concentrations 
of matrine and oxymatrine, these data suggest that drug–drug interactions may occur during 
hOCT1-mediated hepatic and renal uptake and during hOCT3-mediated intestinal 
absorption.     
In addition, we focused on the potential role of OCTs in CNS action of drugs of 
abuse. Synthetic cathinones have recently emerged in the US and Europe and grown to be 
popular drugs of abuse [203, 261]. These drugs have the ability to modulate 
neurotransmitter levels in brain and possess amphetamine-like properties [204-206]. 
Serious adverse effects and deaths are often reported in synthetic cathinone users who 
required medical care [218, 219, 222]. In chapter 6, we explored the inhibitory effects of 
five synthetic cathinones (mephedrone, methylone, methylenedioxypyrovalerone (MDPV), 
R(+)methcathinone and S(-)methcathinone) on hOCT1, hOCT2 and hOCT3. All five 
synthetic cathinones demonstrated marked inhibition of substrate uptake mediated by 
hOCTs. Generally, the inhibitory potencies of test synthetic cathinones for hOCT1 and 
hOCT2 were higher (IC50: 6.5-31.5 µM) than those for hOCT3 (IC50: 130.5-334.7 µM). 
MDPV exhibited the highest potency (lowest IC50 values) for hOCT1 (6.5 ± 1.3 µM), 
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hOCT2 (16.7 ± 1.2 µM) and hOCT3 (130.5 ± 18.0 µM). The optical isomers of 
methcathinone exhibited different patterns of interaction with hOCTs. S(-)methcathinone 
demonstrated higher affinity for hOCT2 as compared to R(+)methcathinone, while the 
inhibitory effect of S(-)methcathinone on hOCT3 was lower than R(+)methcathinone. As 
hOCT2 and hOCT3 are important components of uptake-2 that modulate neurotransmitter 
homeostasis in the CNS, these findings suggested that the psychoactive effects of synthetic 
cathinones for drug abusers might be due to their inhibitory effects on hOCT2 and hOCT3. 
Moreover, cardiovascular complications caused by synthetic cathinones might also be 
caused by their inhibitory effects on hOCT3, since hOCT3 participates in the reuptake of 
NE in cardiac endothelial cells. Finally, the enhanced toxicities of synthetic cathinones 
when coadministered with other stimulants, such as codeine, morphine and heroin, might 
be explained by the high DDI potentials mediated by OCTs. Therefore, the role of OCTs 
in the psychoactive effects/clearance of synthetic cathinones as well as their potential in 
mediating in vivo DDI should be further investigated to elucidate the full mechanistic 
picture.     
The quinazolines and guanidines examined in this work represent a novel series of 
compounds developed as potential drugs that possess antidepressant-like effects. However, 
these compounds failed to produce significant inhibition of uptake-1 activity, since their 
binding affinity for SERT and NET were greater than 10 µM (Dr. Dukat laboratory, 
unpublished data). Based on their physicochemical properties, we hypothesized that these 
compounds might be OCT inhibitors and their antidepressant-like activities might involve 
an uptake-2 mediated mechanism. In chapter 7, we systematically assessed the inhibitory 
effects of thirteen quinazoline and guanidine compounds on three OCTs in two species, 
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human and mouse. At 100 µM, all of test compounds, including 7 novel quinazolines and 
6 guanidines, showed significant inhibition on three hOCTs. The IC50 values for 
unsubstituted quinazoline GSW-286 was smaller than unsubstituted guanidine KAI-323 
(IC50 values: 14.3 ± 2.2 µM v.s. 41.1 ± 14.4 µM). This is probably due to the flexible open 
ring structure of guanidine that decreased the affinity of KAI-323 for hOCTs. In addition, 
it was also observed that chloride, fluoride, methyl and t-butyl substituted quinazoline and 
guanidine compounds have lower IC50 values (2-46 fold) as compared with their 
unsubstituted forms, while benzyl substituted guanidine demonstrated higher (~19 and 5 
fold) the IC50 values for hOCT1 and hOCT3. Since depression is often associated with a 
decreased level of 5-HT in the CNS, OCT inhibition studies were conducted using 
radiolabeled 5-HT as the substrate. The IC50 value for KEO-099 vs 5-HT for hOCT2 was 
determined as 0.56 ± 0.08 µM, which is 29 fold higher than that determined using MPP+. 
This result suggested that a nanomolar level of KEO-099 might be sufficient to provide 
significant inhibition on uptake-2 in brain. Based on in vitro data, we selected three lead 
compounds that showed potent inhibition on both human and mouse OCTs to conduct 
further in vivo studies. KEO-099 demonstrated significant antidepressant-like effects 
during the tail suspension test (TST) with an ED50 value estimated as 0.23 mg/kg, while 
MDA-057 and GSW-286 failed to show significant antidepressant-like effects. This 
antidepressant-like effects of KEO-099 indicated that this compound is permeable across 
the blood brain barrier and is likely to exert its psychiatric effects in brain. Finally, the 
homology modeling of hOCT3 and docking studies were performed based on the 
knowledge of a competitive mechanism of inhibition of test compounds on hOCT3. In the 
docking studies, four key amino acid residues in hOCT3 were identified namely E451 
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(glutamic acid), D478 (aspartic acid), W223 (tryptophan) and F165 (phenylalanine). E451 
and D478 interacted with MPP+ and quinazolines via ionic salt bridge interaction, while 
W223 and F165 interacted with docking compounds through the cation-π interaction. The 
present study suggested that novel OCT inhibitors such as quinazolines have the potential 
to possess antidepressant-like activities, and the hOCT3 homology model could be used as 
a powerful tool for analyzing and predicting the interaction between hOCT3 and small 
molecules in future.   
In chapter 3 to 5, we evaluated DDI potential of OCT- and OAT-mediated drug-
drug interaction for ethambutol, rhein, matrine and oxymatrine. In the future, in vivo DDI 
studies are necessary for these compounds with known substrates for OCTs (e.g. metformin 
and lamivudine) and OATs (e.g., methotrexate) in order to optimize clinical safety and 
efficacy in these complex patient populations. In addition, the present study demonstrated 
that ethambutol, oxymatrine and matrine are inhibitors for OCTs, while rhein is a potent 
inhibitor for OATs. However, it remains unclear whether these compounds are non-
transported inhibitors or actually transporter substrates. This information is key to 
determining whether OCT- or OAT-mediated active uptake is involved in the hepatic 
accumulation or renal elimination of these compounds. As a result, a sensitive, robust, and 
precise bioanalytical method needs to be developed for quantification of these transporter 
inhibitors in cell lysate to address this issue.    
In addition, the role of OCTs in regulating 5-HT, NE and DA clearance in brain 
should be investigated in the following aspects. Firstly, it is important to characterize the 
permeability of quinazoline and guanidine compounds across the blood brain barrier (BBB) 
using appropriate in vitro models. The BBB is a highly selective barrier formed by brain 
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endothelial cells connected by tight junctions that separates the brain interstitial fluid in the 
CNS from the circulating blood [60]. A perquisite for a good CNS drug candidate is that it 
has a high permeability across the BBB; otherwise, it is not easy for the drug to reach its 
target organ. The in vitro cell-based BBB models are more cost-effective than animal 
experiments and have a higher throughput for drug screening. In addition, the permeability 
profiles of test compounds would support the decisions when prioritizing the lead 
compounds. Several in vitro BBB models have been developed, including  steric 
endothelial cells monoculture models, co-culture models of endothelial cells with glial cells, 
as well as more sophisticated 3D dynamic co-culture models of BBB [60]. A number of 
cell lines are available as biological surrogates for BBB, including HMEC-1, HCMEC/D3 
and TY08 [60]. Secondly, it is also important to determine the pharmacokinetics and brain 
distributions of lead compounds in vivo. In the present study, the TST was performed 
following the protocol of Steru et al and Yoshikawa et al [251, 252]. However, the brain 
distribution of lead compounds at 30 min after i.p. injection was not determined, and it is 
possible the compounds achieved their Cmax in brain longer than or shorter than 30 min. 
Information about the pharmacokinetics and the time-course profiles of the brain 
distribution of lead compounds would allow us to better characterize the maximum ED50 
of test compounds in mice. In addition, it would be even more informative if we could 
determine the extracellular regional concentrations of lead compounds by microdialysis in 
specific brain regions, such as hippocampus, frontal cortex and amygdala, where mOct2 
and mOct3 are richly expressed. This would allow extrapolation of in vitro data to 
in vivo level of inhibition on mOct2 and mOct3 in brain. Finally, mOct2 and mOct3 
knockout mice could be used as animal models to test the hypothesis that uptake-2 are the 
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targets for the antidepressant-like effects of guanidine and quinazoline compounds. The 
antidepressant-like effects of test compounds could be compared between wide-type and 
mOct2 or mOct3 knockout mice.       
As for the synthetic cathinones, it is important to find an appropriate animal model 
and conduct in vivo studies to elucidate the contribution of OCTs in the psychoactive 
effects of these compounds. This emphasizes the need to understand the potential species 
differences between human and murine OCTs.  The IC50 values of synthetic cathinones 
should be further determined using murine Oct expressing cell lines. After we identify an 
ideal animal model, the brain extracellular regional distribution of selected synthetic 
cathinones could be determined by microdialysis studies after intravenous administration. 
This information is critical for us to estimate the level of inhibition on Oct2 and Oct3 by 
synthetic cathinones in brain. The psychoactive effects of the synthetic cathinones could 
also be compared between wild-type and Oct2 knockout animal models. Finally, in order 
to evaluate OCT-mediated DDIs, it is necessary to conduct in vivo DDI studies for synthetic 
cathinones and known OCT substrate such as morphine.  
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